JP2011504498A - Topical whitening cosmetic composition and method of use - Google Patents

Abstract

Provided is a topical cosmetic composition that may include a phyllanthus extract, a BelHs extract, and a licorice (Glyciliza) extract. These compositions are used for topical cosmetic applications, in particular for skin whitening. A method of whitening the skin is also provided and may include topically administering to the skin of a subject in need thereof a topical effective amount of a topical cosmetic composition comprising a filanthus extract, a BelHs extract, and a licorice extract.

Description

  The invention described herein relates to a topical cosmetic or dermatological composition comprising a plant extract. These compositions are used for topical cosmetic applications, particularly to treat unwanted skin pigmentation.

  Melanocytes adjacent to the basal cells, found in the lowest layer of the epidermis, the basal layer, are pigmented cells that occur alone or in groups depending on the skin quality. Melanocytes contain melanosomes that form melanin at a higher rate when stimulated by UV irradiation. Melanin is transported to the epidermal cells, resulting in a more or less pronounced tan or brown skin color.

  Melanin is finally converted to melanin by the enzyme tyrosinase via 3,4-dihydroxyphenylalanine (dopa), dopaquinone, leucodopachrome, dopachrome, 5,6-dihydroxyindole and indole-5,6-quinone Is the final product of the oxidation process.

  Safe and effective topical whitening cosmetic compositions are in particular partly caused by hyperfunctioning melanocytes such as idiopathic melasma (gestational melasma or brown spots) occurring during pregnancy or after estrogen-progesterone contraception Hyperpigmentation, local hyperpigmentation caused by benign melanocyte hyperfunction and proliferation such as senile molasses known as melasma, accidental hyperpigmentation such as photosensitization and scarring after injury, skin irritation When age (eg, aging urine) and damaged skin cannot be recolored, whitening or depigmenting the remaining areas of normal skin to whiten the entire skin to a uniform color, such as vitiligo Desirable for the treatment of unwanted skin pigmentation, including certain forms of leukoplakia.

  Several active ingredients and formulations are currently known that whiten the skin, ie suppress skin pigmentation. These products currently in use contain hydroquinone, but such products have recently been considered unacceptable for toxicological reasons. In fact, RDC 215 has prohibited the use of hydroquinone in cosmetic products since December 2007.

  US Patent Application No. 2006/0018867 describes one or more of the polyorganosiloxane-containing epsilon-polylysine compounds obtained by reacting epsilon-polylysine with a polyorganosiloxane or a physiologically acceptable salt thereof and a polyhydric alcohol. A cosmetic composition with improved shelf life and / or antibacterial effect, comprising a combination of two or more, is described which can be a skin lightening composition.

  International PCT Publication No. WO 2004/062635 describes a composition for skin whitening comprising bis-pantoyl-cystamine.

  US Patent Application No. 2004/0028642 describes cosmetic compositions containing extracts of Emblica officinalis and methods for their use.

  US Patent Application 2005/0271608 describes skin whitening compositions based on hydroxyarylalkyl ketones and their isosteric derivatives.

  US Patent Application 2004/166069 describes a method for enhancing the tyrosinase inhibitory activity of skin whitening and sunscreen compositions.

US Patent Application No. 2006/0018867 International Publication No. 2004/062635 Pamphlet US Patent Application No. 2004/0028642 US Patent Application No. 2005/0271608 US Patent Application No. 2004/1666069

  There remains a need in the art for improved topical cosmetic compositions containing agents that whiten the skin safely and effectively. The invention described herein solves these needs by providing a topical cosmetic composition that provides a safe and effective skin whitening upon topical application. Unexpectedly, it has been found that the skin lightening compositions according to the present invention described herein exhibit a synergistic skin lightening effect. The synergistic skin whitening effect leads to a composition that allows a reduction in the amount of skin whitening active ingredient used when formulating a topical cosmetic composition, then reduces the potential for irritation and reduces material costs.

  The present invention relates generally to topical cosmetic compositions useful for treating various skin disorders or conditions associated with undesirable skin pigmentation. Furthermore, the present invention relates to a topical cosmetic composition useful for whitening skin areas where skin deposition is suitable for the skin quality of an individual by makeup.

  In one embodiment, the present invention relates to a topical cosmetic composition comprising or consisting of a Phyllanthus extract, a Bellis extract and a licorice extract.

  In one embodiment, the present invention relates to a topical cosmetic composition comprising or consisting of Phyllanthus embilica extract, Bellis perennis extract and licorice extract.

  In another embodiment, the present invention comprises a skin lightening active ingredient, or at least one sunscreen, and a cosmetically acceptable carrier comprising or consisting of a philanthus extract, belis extract and licorice extract. For topical cosmetic compositions comprising or consisting of.

  In another embodiment, the present invention provides a skin whitening active ingredient, at least one sunscreen, and cosmetics comprising or consisting of Filanthus Emblica extract, Belis Perennis extract and Licorice extract It relates to topical cosmetic compositions comprising or consisting of acceptable carriers.

  In one embodiment, the present invention comprises a skin lightening active ingredient comprising or consisting of a philanthus extract, a beris extract and a licorice extract, and a non-skin whitening ingredient comprising at least one sunscreen. It relates to a topical cosmetic composition comprising or consisting of them.

  In one embodiment, the present invention comprises a skin lightening active ingredient comprising or consisting of a Filanthus embrica extract, a Belis perennis extract and a licorice extract, and a non-sun containing at least one sunscreen. It relates to a topical cosmetic composition comprising or consisting of a skin whitening component.

  In another embodiment, the present invention is a method for whitening skin pigmentation in a subject, wherein a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein is applied to the skin of the subject in need thereof. It relates to a method comprising topical administration.

  In yet another embodiment, the present invention is a method of treating a skin disorder or condition in a subject, wherein the subject in need thereof has a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein. It relates to a method comprising topical administration to the skin.

FIG. 2 is a graph showing progressive whitening over time that became statistically significant after 21 days for site B treated with 2% hydroquinone. It is a figure which shows the progressive whitening which became statistically significant after 14 days about the site | part E treated with the topical cosmetic composition of this invention with time. FIG. 5 shows progressive whitening (natural degradation of synthesized melamine) with no significance during the experimental time for an untreated control site (site F). FIG. 5 shows a comparison of the average of colorimeter values between treatments 1 (site B) and 2 (site E) and control (site F) during the evaluation time.

Definitions As used herein, terms such as “administering”, “administration” and the like are intended in a way that has a positive effect on a dermatological disorder, condition or appearance in a healthy medical or cosmetic act. Means any method of delivering the composition. The composition can be administered to cover the entire area to be treated. “Direct administration” means any method of delivering a composition to a subject in a healthy medical or cosmetic practice without the use of another composition, delivery agent, or device. “Indirect administration” means any method of delivering a composition to a subject using at least another composition, delivery agent, or device in sound medical or cosmetic practice.

  As used herein, “aqueous solvent” means a solvent such as water or a solvent containing water. Other dissolved components, such as salts, buffers, and other components understood by those skilled in the art as desired in aqueous solutions, may be present in small amounts.

  “Anhydrous formulation” means any formulation of the topical cosmetic composition of the present invention that does not contain water.

  “Cosmetically acceptable” means a non-toxic, inert, and / or physiologically compatible composition.

  As used herein, the phrase “effective amount” or “therapeutically effective amount” of an active agent or ingredient as defined herein means the amount of active agent sufficient to have a positive effect on the area of application. To do. Therefore, these amounts are sufficient to change the skin disorder, condition or appearance to be treated, within sound medical or dermatological judgment, but not enough to avoid serious side effects Few. A therapeutically effective amount of the active agent provides substantial relief of symptoms when applied repeatedly over time. The effective amount of the active agent will vary with factors such as the particular condition or condition being treated, the severity of the condition, the duration of treatment, the particular components of the composition used.

  As used herein, “providing” is a process that produces an effect on the biological activity, function, health or condition of an organism and maintains such activity in a manner consistent with the general health and health of the organism. Means the process of augmenting, reducing or providing.

  As used herein, “enhancing” the biological activity, function, health or condition of an organism means a process of increasing, reinforcing, enhancing or improving the biological activity, function, health or condition.

  As used herein, “epithelial” or “epithelial” means the layer of cells that form the epidermis of the skin and the surface layer of the mucosa and serosa. Epithelial cells have general functions of defense, absorption and secretion. Epithelial cells are often close to blood vessels, but generally lack a direct blood supply.

  As used herein, “extract” means one or more components isolated from a plant material in liquid or powder form. The plant material may comprise or consist of the entire plant or one or more parts of the plant, for example, plant fruits, flowers, roots, leaves, stems and / or bark. The liquid or liquid extract can be dried, eg, spray dried or dried to form a powder. The extract can be a mixture of one or more components of the plant in liquid and / or powder form.

  “Non-skin whitening” includes any compound, substance or composition, or drug, or one or more drugs, substances and compositions that do not depigment or whiten the skin when topically applied to the skin, or The component comprised from them is meant. Such agents are described, for example, as described herein, for example, one or more active agents, such as sunscreens, anti-acne agents, antibacterial agents, anti-wrinkle agents, anti-atrophy agents, anti-inflammatory agents, and Optical brightener and / or one or more cosmetically acceptable excipients, such as thickeners, chelating agents, humectants, emollients, wetting agents, gelling agents, pH adjusting agents, Surfactants, stabilizers, vitamins, penetration enhancers, perfumes, colorants, solvents, and / or combinations thereof may be included.

  As used herein, “penetration enhancer” means a compound, substance or composition that reversibly reduces the barrier resistance of the stratum corneum of the skin and allows the active agent to reach the living tissue at a faster rate.

  As used herein, “pH adjuster” or “pH adjuster” means a specific pH adjuster added to a composition to give the composition a specific indicated pH.

  As used herein, “pharmaceutically acceptable free base, salt, ester, or solvate” has the same pharmacological activity as the target compound (s) and Means the free base, salt, ester, or solvate of the target compound (s) that is not undesirable in this respect. Salts, esters or solvates can be formed, for example, with organic or inorganic acids. Non-limiting examples of suitable acids include acetic acid, acetylsalicylic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, bisulfic acid, boric acid, butyric acid, camphoric acid, camphor Sulfonic acid, carbonic acid, citric acid, cyclopentanepropionic acid, digluconic acid, dodecylsulfuric acid, ethanesulfonic acid, formic acid, fumaric acid, glyceric acid, glycerophosphoric acid, glycine, glucoheptanoic acid, gluconic acid, glutamic acid, glutaric acid, glycolic acid , Hemisulfuric acid, heptanoic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucoic acid , Naphthylenesulfonic acid, naphthylic acid, nicotinic acid, nitrous acid, Uric acid, pelargonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, sorbic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, thioglycolic acid, thiosulfuric acid, tosylic acid, undecylenic acid, ethanolamine, natural and synthetic amino acids Is mentioned. Non-limiting examples of base salts, esters or solvates include ammonium salts; alkali metal salts such as sodium and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; organic base salts such as dicyclohexyl Amine salts; methyl-D-glucamine and amino acid salts such as arginine, lysine and the like are included. Also, basic nitrogen-containing groups include lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromide, and iodide; dialkyl sulfates such as dimethyl, diethyl, dibutyl, and diamyl sulfate; long chain halogens Can be quaternized with agents such as decyl, lauryl, myristyl, and stearyl chloride, bromide, and iodide; asthma halides such as benzyl and phenethyl bromide. Water or oil-soluble or dispersible products are thereby obtained.

  As used herein, “serum” means a hydrophilic liquid formulation. The serum may optionally be free of one or more emollients, waxes and silicones.

  As used herein, “skin whitening agent” means any compound, substance or composition that whitens or depigments the skin when topically applied to the skin. Such skin lightening agents can include, but are not limited to, pigmentation inhibitors, tyrosinase inhibitors, and melanogenesis inhibitors of melanocytes.

  As used herein, a “subject” or “individual” or “animal” or “patient” or “mammal” is any subject for which diagnosis, prevention or treatment is desired, particularly a mammalian subject, eg, a human.

  As used herein, “synergistic skin lightening system” or “synergistic skin lightening component” includes or consists of a Filanthus embrica extract, a belith perennis extract, a licorice extract, each individually The skin whitening active ingredient which shows a synergistic skin whitening effect compared with the skin whitening effect of the skin whitening active agent. In this respect, the combination of these components provides a greater effect than the additive skin whitening effect.

  As used herein, “treatment” or “treating” of a skin disease, disorder, or condition includes alleviating at least one symptom thereof, reducing their severity, or delaying, preventing their progression. Or inhibition is included. Treatment need not imply complete cure of the disease, disorder or condition. The compositions useful herein reduce the severity of a skin disease, disorder or condition, reduce the severity of symptoms associated therewith, improve the patient's quality of life, or skin disease, disorder Or only necessary to delay, prevent or inhibit the onset of the condition.

  As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. pay attention to.

  Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention described herein pertains.

  Where a range of values is provided, e.g., a concentration range, a percentage range, or a ratio range, each intervening value between the upper and lower limits of the range is the lower limit unless the context clearly dictates otherwise. It is understood that up to one-tenth of a unit and other specified values or specified intervening values within the specified range are included within the scope of the described invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and such embodiments are also described according to any specifically excluded limits within the specified ranges. Included within the scope of the present invention. Where the specified range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the described invention.

  Throughout the application, the description of various embodiments uses the phrase “comprising”, but in some specific cases, embodiments may alternatively be “consisting essentially of” or One skilled in the art will understand that the phrase “consisting of” can be used to describe.

  In order to better understand the teachings of the present invention and not to limit the scope of the teachings in any way, all of the numbers, proportions or ratios used in the specification and claims, and others, unless otherwise stated It should be understood that in each case the number is modified by the term “about”. Accordingly, unless stated to the contrary, the numerical parameters set forth in the following specification and appended claims are approximations that can vary depending upon the desired properties sought to be obtained. At a minimum, each numeric parameter should be interpreted by applying the usual rounding method, taking into account at least the reported number of significant digits.

The present invention relates to a topical cosmetic composition comprising or consisting of a philanthus extract, a belith extract and a licorice extract.

Main skin lightening actives According to the invention described herein, the topical cosmetic composition of the invention comprises a philanthus extract, ie, a philanthus embrica extract, a belith extract, ie, a belis perrennis extract. And licorice extract or may consist of them.

  “Philanthus extract” refers to, for example, Phyllantus embilica, Phyllantus niruuri L. , Phyllantus elegans Wall, Phyllantus iniruri, Phyllantus reticulatus, Phyllantus urinaria L. , Phyllantus reticulatus Poir, Phyllantus conami Sw, Phyllantus lathyroides H. et al. B. K. Means an extract obtained from a group of fruits of the genus Philanthus including Phyllanthus casticum Soy-Will and Phyllanthus medagascariensis. Filanthus extract is a safe and effective natural antioxidant.

  “Filans Emblica extract” includes, for example, a standardized extract of Philanthus Emblica, including EMBLICA® (a branch of Merck KGaA, Darmstadt, Germany and EM industries, Inc., USA, Merck KGaA). means. Philanthus Emblica, also commonly known as “Embilica officinalis Gaertn”, is a member of the family “Euphorbiaceae”. Philanthus Emblica is a very rich source of vitamin C and has an ascorbic acid content in the range of 1000-1800 mg per 100 grams of fruit. Philanthus Emblica extract is a safe and effective natural antioxidant that has no oxidation-inducing activity and can exhibit bifunctionality, ie chelation and antioxidant. Unlike most antioxidants that go from the active form to the inactive form, the extract of Philanthus embrica can exhibit a cascade effect that provides a long-lasting, stable antioxidant activity. The Filansas Emblica extract is produced by extracting high quality fruit using a water based process as described in US Pat. No. 6,124,268, which is incorporated herein by reference in its entirety. Can do. Philanthus embrica extract generally contains low molecular weight tannins, so-called embricanin A and embricanin B, together with pedunclazine and punygluconin, rutin and gallo-elagitanoid.

  “Bellis extract” includes, for example, an extract obtained from a flower of a member of the genus Beris, for example, a flower of Belis Perennis and / or a flower of Belis rotundifolia L. It means an extract obtained from a group of genus Belis. The Belis extract may contain or consist of one or more bioactive molecules including saponins (triterpene glycosides), polyphenols (phenolic acid), flavonoid glycosides, polysaccharides and inulins.

  A “Beris Perennis extract” comprises or is composed of one or more bioactive molecules including saponins (triterpene glycosides), polyphenols (phenolic acid), flavonoid glycosides, polysaccharides and inulins. It means an extract obtained from Perennis flowers. A suitable Belis Perennis extract may include BELIDES® available from CLR Chemisches Laboratorium, Berlin, Germany. Bellis perennis is also described in Bellis alpina Hegetschw. Bellis hortensis Mill. Bellis hybrida Ten. Bellis integrifolia DC. And commonly known as Bellis scaposa Gilib.

  A “licorice extract” means an extract obtained from a group of genus Glycyrrhiza, for example, from a group of roots of the genus Glycyrrhiza. The genus “Glyciliza” is a member of the “Fabaceae” family. Suitable glycyrrhisa extracts can include oil-soluble licorice extracts available from Bioland, Korea. Other suitable glycyrrhaza extracts are available from Glycyrrhiza echinata L. (Chinese licorice), Glycyrrhiza glabra L. et al. (Cultivated licorice), Glycyrrhiza lepidota L. Glycyrrhiza glutinosa, polypodium Glycyrrhiza, Glycyrrhiza brachycarpa Boiss. Glycyrrhiza germanica Tourn. Glycyrrhiza grandilifera Waldst. et Kit. Glycyrrhiza hirsuta L .; Glycyrrhiza laevis Pall. Glycyrrhiza offcinalis Lepech. Glycyrrhiza pallida Boys. Glycyrrhiza siliqosa Tour. Glycyrrhiza violacea Boys. Glycyrrhiza viscose Turcz. ex Ledeb. Glycyrrhiza vulgaris Gueldenst. It can be obtained from one or more of a group of Glycilizae, including ex Ledeb, Liquiritia officinalis Moench and Liquiritia officinalum Medik.

  In one embodiment, the topical cosmetic composition of the present invention may comprise or consist of a skin lightening active ingredient that may comprise or consist of a philanthus extract, a beris extract and a licorice extract.

  In one embodiment, the topical cosmetic composition of the present invention comprises or consists of a skin lightening active ingredient that may comprise or consist of a Filanthus embrica extract, a belith perennis extract and a licorice extract. Can be configured.

  In one embodiment, the invention provides that the topical skin lightening active ingredient is from about 0.5% to about 43%, from about 1% to about 30%, about 1.5% by weight based on the total weight of the composition. To about 23%, about 1.5% to about 15%, about 3% to about 10%, about 6% to about 8%, or about 7.05% by weight The present invention relates to a topical cosmetic composition present in a cosmetic composition.

  In another embodiment, the present invention relates to a phyllanthus extract, for example, a philanthus embrica extract, from about 0.1% to about 8%, from about 0.25% to about 4%, based on the total weight of the composition. In a topical cosmetic composition in an amount of about 0.5%, about 0.5% to about 3%, about 0.5% to about 2%, about 1% to about 2% or about 2% by weight. The present invention relates to a topical cosmetic composition.

  In other embodiments, the present invention provides a belis extract, such as a belis perennis extract, from about 0.5% to about 30%, from about 1% to about 20% by weight, based on the total weight of the composition. Topical cosmetic composition present in an amount of about 2% to about 10%, about 3% to about 7%, about 4% to about 6% or about 0.5% by weight The present invention relates to a cosmetic composition.

  In yet another embodiment, the invention provides that the licorice extract is about 0.005% to about 5%, about 0.01% to about 2%, about 0.01%, based on the total weight of the composition. In a topical cosmetic composition in an amount of from wt% to about 1 wt%, from about 0.02 wt% to about 0.08 wt%, from about 0.03 wt% to about 0.07 wt% or about 0.05 wt% The present invention relates to a topical cosmetic composition.

  In another embodiment, the present invention provides a phyllanthus extract, such as a philanthus embrica extract, present in a topical cosmetic composition in an amount of about 0.50 wt% to about 2 wt%, A topical cosmetic wherein the perennial extract is present in the topical cosmetic composition in an amount of about 1 wt% to about 20 wt% and the licorice extract is present in the topical cosmetic composition in an amount of about 0.01 wt% to about 1 wt%. Relates to the composition.

  In yet another embodiment, the present invention relates to a licorice extract wherein the philanthus embrica extract is present in the topical cosmetic composition in an amount of about 2 wt%, the belith perennis extract is present in an amount of about 5 wt%. The topical cosmetic composition wherein the product is present in the topical cosmetic composition in an amount of about 0.05 wt%.

  In one embodiment, the present invention comprises a skin lightening activity comprising or consisting of a philanthus extract, such as a philanthus emblica extract, a belis extract, such as a belis perrennis extract, and a licorice extract. It relates to a topical cosmetic composition comprising or consisting of the ingredients, at least one sunscreen, and a cosmetically acceptable carrier. A cosmetically acceptable carrier may comprise or consist of one or more cosmetically acceptable excipients.

  In another embodiment, the present invention comprises a skin whitening comprising or consisting of a philanthus extract, for example, a philanthus embrica extract, a belis extract, such as a belis perennis extract, and a licorice extract. It relates to a topical cosmetic composition comprising or consisting of active ingredients and non-skin whitening ingredients. Does the non-skin whitening component include one or more active agents, such as sunscreens, cosmetically acceptable carriers, and / or cosmetically acceptable excipients as described herein? Or may consist of them.

  In other embodiments, the present invention relates to a topical cosmetic composition according to the present invention as described herein, which may comprise one or more non-skin whitening active ingredients.

  In yet another embodiment, the topical cosmetic composition and / or the cosmetically acceptable carrier and / or the one or more cosmetically acceptable excipients are a philanthus extract, such as a filanthus extract extract, It can be free of any skin lightening agents other than Belis extract, such as Belis Perennis extract and Licorice extract. A topical cosmetic composition and / or a cosmetically acceptable carrier and / or one or more cosmetically acceptable excipients may be a phyllanthus extract, such as a philanthus embrica extract, a belis extract, such as a belis -It can be free of any plant-derived skin lightening agent other than Perennis extract and Licorice extract. The topical cosmetic composition and / or the cosmetically acceptable carrier and / or one or more cosmetically acceptable excipients can be free of any non-vegetable skin lightening agent.

  In one embodiment, the present invention provides that the composition and / or skin whitening active ingredient and / or non-skin whitening ingredient does not contain hydroquinone or a derivative thereof and / or does not contain a polyorganosiloxane-containing epsilon-polylysine compound, and It relates to a topical cosmetic composition which does not contain flavans.

Synergistic skin lightening ingredients In another embodiment, the present invention comprises or comprises a phyllanthus extract, such as a philanthus embrica extract, a belis extract, such as a belis perennis extract, and a licorice extract. A synergistic skin whitening active ingredient can be included or configured, each synergistic skin whitening active ingredient having a synergistic skin whitening effect compared to the skin whitening effect of each individual skin whitening active ingredient. The topical cosmetic composition represented.

  In one embodiment, the present invention provides a topical cosmetic composition comprising or consisting of a phyllanthus extract, such as a philanthus embrica extract, a belis extract, such as a belis perennis extract, and a licorice extract. The invention relates to a synergistic skin lightening ingredient for use in products.

  In another embodiment, the present invention provides a topical application comprising or consisting of a philanthus extract, such as a philanthus embrica extract, a belis extract, such as a belis perrennis extract, and a licorice extract. A synergistic skin lightening ingredient for use in a cosmetic composition, which relates to a synergistic skin whitening ingredient that exhibits enhanced skin whitening effects. The synergistic skin lightening component can be free of hydroquinone.

  In one embodiment, the topical cosmetic composition according to the invention described herein may comprise or consist of a skin lightening active ingredient that exhibits a synergistic skin lightening effect.

  In other embodiments, the topical cosmetic composition according to the invention described herein may comprise or consist of a skin lightening active ingredient that exhibits a synergistic skin lightening effect, wherein the topical cosmetic composition comprises hydroquinone. Not included.

  In one embodiment, the topical cosmetic composition or synergistic skin lightening system according to the present invention as described herein may comprise or consist of a skin lightening active ingredient that exhibits a synergistic skin lightening effect, and is a topical cosmetic. The composition is free of hydroquinone and / or flavan and / or polyorganosiloxane-containing epsilon-polylysine compounds.

Cosmetically acceptable carriers Any non-toxic, inert and effective topical cosmetically acceptable carrier can be used to formulate the compositions described herein. Well known carriers used to formulate other topical therapeutic compositions for administration to humans are useful for these compositions. Examples of these ingredients well known to those skilled in the art are described in The Merck Index, 13th edition, edited by Budavari et al., Merck & Co., the entire contents of which are hereby incorporated by reference. , Inc. Rahway, N .; J. et al. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Indigenous Dictation and Handbook, 10th edition (2004); S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, January 1996. Examples of such useful cosmetically acceptable excipients, carriers and diluents include those suitable for use herein in distilled water, physiological saline, Ringer's solution, dextrose solution, Hanks solution and DMSO are included.

  These additional other inactive ingredients as well as effective formulation and administration methods are well known in the art, both of which are hereby incorporated by reference. Goodman and Gilman's: The Pharmacologic Bases of Therapeutics, 8th edition, edited by Gilman et al., Pergamon Press (1990) and Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Co. Easton, Pa. (1990).

Sunscreen In another embodiment, the present invention relates to a topical cosmetic composition that may comprise at least one sunscreen. The at least one sunscreen is in an amount of about 0.5% to about 30%, about 1% to about 20%, or about 1% to about 10% by weight based on the total weight of the composition. Can exist.

  Suitable sunscreens may include a broad spectrum sunscreen that protects against both UVA and UVB radiation or a sunscreen that protects against UVA or UVB radiation. Non-limiting examples of suitable sunscreens include 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N, N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole-5- Sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4′-methoxy-t-butyldibenzoylmethane, 4-isopropyldibenzoylmethane, 3-benzylidenecamphor, 3- (4-methylbenzylidene) camphor, 2 Titanium oxide, zinc oxide, silica, iron oxide, 4-N, N- (2-ethylhexyl) methylaminobenzoate of 2,4-dihydroxybenzophenone, 4-N, N- (with 4-hydroxydibenzoylmethane 2-Ethylhexyl) -methylaminobenzoate Acid ester, 4-N, N- (2-ethylhexyl) -methylaminobenzoate of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone, 4-N of 4- (2-hydroxyethoxy) benzoylmethane, N- (2-ethylhexyl) -methylaminobenzoic acid ester, dihydroxycinnamic acid, trihydroxycinnamic acid, diphenylbutadiene, stilbene, dibenzalacetone, benzalacetophenone, naphthol sulfonate, 2-naphthol-3,6- Disulfonic acid, 2-naphthol-6,8-disulfonic acid, dihydroxynaphthoic acid, o- and p-hydroxybiphenyl disulfonate, coumarin, diazole, 2-acetyl-3-bromoindazole, phenylbenzoxazole, methylnaphthoxazole, Mr Arylbenzothiazole, quinine salt, quinoline derivative, 8-hydroxyquinoline, 2-phenylquinoline, hydroxy and methoxy substituted benzophenone, uric acid, violuric acid, tannic acid, benzophenone, oxybenzene, thrisobenzone, dioxybenzone, benzoresorcinol, 2, 2 ′, 4,4′-tetrahydroxybenzophenone, 2,2′-dihydroxy-4,4′-dimethoxybenzophenone, octabenzone, 4-isopropyldibenzoylmethane, butylmethoxydibenzoylmethane, ethocrylene, octocrylene, 3- (4 '-Methylbenzylideneboman-2-one), terephthalylidene dicamphorsulfonic acid, 4-isopropyl-di-benzoylmethane, butylmethoxydibenzoyl-methane, 2-hydroxy 4-N, N- (2-ethylhexyl) methyl-amino of droxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene, 2,4-dihydroxybenzophenone Benzoic acid ester, 4-hydroxybenzoylmethane, N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester, 4- (2-hydroxyethoxy) dibenzoylmethane 4-N, N- (2 -Ethylhexyl) -methylaminobenzoate, N, N- (2-ethylhexyl) -4-methylaminobenzoate of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone, 4- (2-hydroxyethoxy) N, N-di- (2-ethylhexyl) of dibenzoylmethane 4-aminobenzoic acid esters, their pharmaceutically or comprise one or more of acceptable acceptable salts and mixtures thereof as a cosmetic or sunscreen may consist thereof.

  In one embodiment, the topical cosmetic composition of the present invention comprises methylene bisbenzotriazolyl tetramethylphenol, diethylaminohydroxybenzoyl hexyl benzoate, coated zinc oxide, ethyl hexyl methoxycinnamate, isoamyl methoxycinnamate, homosalate salicylic acid. Sunscreens comprising or consisting of one or more of ethylhexyl, octocrylene, polysilicone-15, butylmethoxydibenzoylmethane, menthyl anthranilate and ethylhexyldimethyl PABA may be included.

  In a further embodiment, the topical cosmetic composition of the present invention comprises one or more of methylene bis-benzotriazolyl tetramethylphenol (TINOSORB M available from CIBA), diethylaminohydroxybenzoyl hexyl benzoate and coated zinc oxide. Sunscreens may be included, including in an amount of about 1% to about 20%, about 2% to about 10%, or about 5% by weight based on the total weight of the composition. For example, the topical cosmetic composition of the present invention comprises methylene bis-benzotriazolyl tetramethylphenol from about 1% to about 20%, from about 2% to about 10%, or from about 1% by weight based on the total weight of the composition. Sunscreens can be included in an amount of 5% by weight or composed thereof.

  In other embodiments, the topical cosmetic composition of the present invention comprises ethylhexyl methoxycinnamate (available from BASF), isoamyl methoxycinnamate, ethylhexyl homosalate salicylate, octocrylene, polysilicone-15, butylmethoxydibenzoylmethane, One or more of menthyl anthranilate and ethylhexyl dimethyl PABA in an amount of about 1% to about 10%, about 5% to about 9%, or about 7.5% by weight, based on the total weight of the composition. Sunscreens comprising or consisting of them may be included.

  In one embodiment, the topical cosmetic composition of the present invention comprises from about 0.5% to about 30%, from about 1% to about 20% by weight of one or more sunscreens, based on the total weight of the composition. Or about 1% to about 10% by weight.

  In one embodiment, the at least one sunscreen is a first sunscreen selected from the group consisting of methylene bisbenzotriazolyl tetramethylphenol, diethylaminohydroxybenzoyl hexyl benzoate, coated zinc oxide, and methoxy cinnamon. A second sunscreen selected from the group consisting of ethylhexyl acid, isoamyl methoxycinnamate, ethylhexyl homosalate salicylate, octocrylene, polysilicone-15, butylmethoxydibenzoylmethane, menthyl anthranilate and ethylhexyldimethyl PABA, Or they can be composed of them. The first sunscreen is present in an amount of about 1% to about 20% by weight, and the second sunscreen is in an amount of about 1% to about 10% by weight, based on the total weight of the topical cosmetic composition. Can exist. The first sunscreen may comprise or consist of methylene bis-benzotriazolyl tetramethylphenol, and the second sunscreen may comprise or consist of ethylhexyl methoxycinnamate.

  In one embodiment, the invention provides an SPF greater than about 10, SPF greater than about 15, SPF at least about 15, SPF about 15, SPF about 10 to about 45, SPF about 15 to about 45, Or a topical cosmetic composition having an SPF of about 15 to about 25.

Aqueous Solvent The topical cosmetic composition of the present invention may further comprise an aqueous solvent. In one embodiment, the composition of the present invention comprises an aqueous solvent, such as water, from about 5% to about 95%, from about 10% to about 90%, about 25% by weight, based on the total weight of the composition. To about 80%, about 55% to about 75%, about 60% to about 70% or about 63% by weight.

Cosmetically acceptable excipients In yet another embodiment, the present invention relates to a topical cosmetic composition that may comprise water and at least one cosmetically acceptable excipient. Suitable cosmetically acceptable excipients include those commonly known to those skilled in the art to be useful in topical compositions.

  In one embodiment, the at least one cosmetically acceptable excipient is an antioxidant, chelating agent, pH adjusting agent, emollient, thickener, gelling agent, free radical scavenger, preservative. , Emulsifiers, wetting agents, humectants, suspending agents, surfactants, stabilizers, vitamins, penetration enhancers, perfumes or fragrances, colorants, liquid alkyl alcohols, polysiloxanes, modified polysiloxanes and combinations thereof It can comprise or consist of one or more components selected from the group.

Antioxidants The topical cosmetic composition may optionally further comprise one or more antioxidants. If desired, suitable antioxidants that can be included in these compositions are ascorbic acid, ascorbyl esters of fatty acids, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate, tocopherol, tocopherol sorbate, tocopherol acetate, butyl acetate Hydroxybenzoic acid, thioglycolate, persulfate, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, lipoic acid, gallic acid, propyl gallate, uric acid, sorbic acid, lipo Acid, amine, N, N-diethylhydroxylamine, N-acetyl-L-cysteine, aminoguanidine, sulfhydryl compound, glutathione, dihydroxyfumaric acid, lysine pidolate, arginine pyrolate, nordihydroguaiaretic acid, biophra Contains one or more of a noid, curcumin, lysine, 1-methionine, proline, superoxide dismutase, silymarin, tea extract, grape bark / seed extract, melanin, rosemary extract, derivatives thereof and combinations thereof Or may consist of them.

  In one embodiment, the topical cosmetic composition of the present invention comprises one or more of butylated hydroxytoluene, sodium metabisulfite, butylated hydroxylanisole, ascorbic acid and derivatives thereof, sulfite and derivatives thereof, esters and tocopherol acetate. For example, from about 0.01% to about 0.5%, from about 0.01% to about 0.2%, from about 0.02% to about 0.1%, based on the total weight of the composition. A suitable antioxidant may be included, or may be comprised in an amount of from wt%, from about 0.03 wt% to about 0.07 wt% or about 0.05 wt%. The topical cosmetic composition of the present invention contains sodium metabisulfite, for example, from about 0.1% to about 0.5%, from about 0.2% to about 0.4% by weight based on the total weight of the composition. %, Or about 0.3% by weight. Further, the topical cosmetic composition of the present invention contains butylated hydroxytoluene, for example, from about 0.01% to about 0.2%, from about 0.02% to about 0.02%, based on the total weight of the composition. It may be included in an amount of 1% by weight, about 0.03% by weight to about 0.07% by weight, or about 0.05% by weight. The topical cosmetic composition of the present invention contains butylated hydroxytoluene and sodium metabisulfite, for example from about 0.01 wt% to about 0.6 wt%, from about 0.2 wt%, based on the total weight of the composition. An antioxidant may be included, which may be included in or composed of about 0.5% by weight, or about 0.35% by weight combined.

  The one or more antioxidants are included in the topical cosmetic composition, for example, from about 0.01% to about 0.6%, from about 0.1% to about 0.00%, based on the total weight of the composition. It may be present in an amount of 5% by weight, or from about 0.2% to about 0.5% by weight.

Chelating agents The topical cosmetic compositions of the present invention may optionally further comprise one or more chelating agents. Suitable chelating agents that may optionally be included in these compositions are citric acid, (mono) isopropyl citrate, stearyl citrate, lecithin citrate, gluconic acid, tartaric acid, oxalic acid, phosphoric acid, sodium tetrapyrophosphate , Potassium monophosphate, sodium hexametaphosphate, calcium hexametaphosphate, sorbitol, glycine (aminoacetic acid), methylglucamine, triethanolamine (trolamine), EDTA, DEG (dihydroxyethylglycine), DPTA (diethylenetriaminepentaacetic acid), NTA (nitrilotriacetic acid), HEDTA (N- (hydroxyethyl) -ethylenetriaminetriacetic acid), aminocarboxylate, dimercaprol (BAL), larixic acid (maltol), monodentate ligands (fluorine and cyanide) ON), diphenylthiocarbazone, O-phenanthroline, barium diphenylaminesulfonate, sodium glucoheptonate, 8-hydroxyquinoline, olefin complexes (eg dicyclopentadienyl iron), porphyrins, phosphates, pharmaceuticals thereof Or it may comprise or consist of one or more of cosmetically acceptable salts, derivatives thereof and mixtures thereof.

  The topical cosmetic compositions of the present invention can comprise from about 0.05% to about 1%, from about 0.1% to about 0.5%, or about 0.2% by weight based on the total weight of the composition. One or more chelating agents present in an amount may be included.

  In one embodiment, the topical cosmetic composition of the present invention comprises one or more of edetate disodium, EDTA, disodium EDTA, trisodium EDTA, and tetrasodium EDTA, for example, about 0.00% of the total weight of the composition. Chelating agents can be included that can be included in an amount from 2% to about 0.4% by weight.

pH adjuster The topical cosmetic composition of the present invention may optionally further comprise one or more pH adjusters. Suitable neutralization pH adjusters that may optionally be included in these compositions include one or more of inorganic hydroxides, inorganic oxides, inorganic salts of weak acids, derivatives thereof and mixtures thereof, or They can consist of them.

  Suitable inorganic hydroxides useful in this regard include or are one or more of ammonium hydroxide, alkali metal hydroxides, alkaline earth metal hydroxides, derivatives thereof and mixtures thereof. Can be configured.

  Suitable inorganic hydroxides useful in this regard are ammonium hydroxide, monovalent alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, divalent alkaline earth metal hydroxides such as calcium hydroxide. And may comprise or consist of one or more of magnesium hydroxide, derivatives thereof and mixtures thereof.

  Suitable inorganic oxides useful in this regard may comprise or consist of one or more of magnesium oxide, calcium oxide, derivatives thereof and mixtures thereof.

  Suitable inorganic salts useful in this regard include ammonium phosphate (dibasic), alkali metal salts of weak acids such as sodium acetate, sodium borate, sodium metaborate, sodium carbonate, sodium bicarbonate, sodium phosphate (Tribasic), sodium phosphate (dibasic), potassium carbonate, potassium bicarbonate, potassium citrate, potassium acetate, potassium phosphate (dibasic), potassium phosphate (tribasic), weak acid alkali It may comprise or consist of one or more of earth metal salts such as magnesium phosphate and calcium phosphate, derivatives thereof and mixtures thereof.

  In one embodiment, the topical cosmetic composition of the present invention may comprise a pH adjuster that may comprise or consist of one or more of triethanolamine, aminomethylpropanol and sodium hydroxide. The pH adjuster is present in the composition, for example, from about 0.1% to about 1%, from about 0.2% to about 0.9%, or about 0.6% by weight based on the total weight of the composition. % May be present. The topical cosmetic composition of the present invention may have a pH in the range of about 2.5 to about 8 or about 3 to about 7.

Emollient The topical cosmetic composition of the present invention may further comprise an emollient. Suitable non-limiting examples of emollients useful in the compositions of the present invention include one or more myristyl lactate, isopropyl palmitate, light liquid paraffin, cetearyl alcohol, lanolin, lanolin derivatives, mineral oil, Vaseline, cetyl ester wax, cholesterol, glycerol, glycerol monostearate, isopropyl myristate, glycol, lecithin and mixtures thereof are included.

  In one embodiment, suitable emollients are one or more glycerin, glycols such as propylene glycol, butylene glycol and pentylene glycol, cyclopentasiloxane dimethicone crosspolymer (DC9040 available from Dow Corning), cyclo It may comprise or consist of pentanesiloxane PEG / PEG-18 / 18 dimethicone (DC5225C available from Dow Corning), and silicon derivatives. The emollient can be present in an amount of about 1% to about 20%, about 2% to about 10%, about 3% to about 8%, or about 4% by weight.

Thickener / gelator The topical cosmetic composition of the present invention may optionally further comprise one or more thickeners. Suitable thickeners that may optionally be included in these compositions include, but are not limited to, one or more cellulose polymers such as gum arabic, gum tragacanth, locust bean gum, guar gum, xanthan gum, cellulose gum, Carbomer sodium; carbomer; polyacrylic polymer; aqueous gelling agents such as neutral, anionic and cationic polymers; polymers such as carboxyvinyl polymers such as carboxypolymethylene Acrylic acid copolymers; polysorbates; fatty acid alcohols such as cetyl alcohol and stearyl alcohol; glyceryl stearate; alkyl derivatives Or comprising a body, and mixtures thereof, or can be constructed from them. Suitable acrylic acid copolymers can include or consist of, but are not limited to, one or more hydroxyethyl acrylate and sodium acryloyldimethyltaurate copolymers.

  In one embodiment, suitable thickeners are, for example, from about 0.25% to about 4%, from about 0.5% to about 3%, from about 1% by weight, based on the total weight of the composition. One or more fatty acid alcohols, such as cetyl alcohol and stearyl alcohol; glyceryl stearate; alkyl derivatives and combinations thereof, present in or composed of about 2% or about 2% by weight sell.

  In one embodiment, suitable thickeners are, for example, from about 1% to about 10%, from about 2% to about 8%, from about 3% to about 7% by weight, based on the total weight of the composition. Or one or more hydroxyethyl acrylate, sodium acryloyldimethyltaurate copolymer, squalane, polysorbate 60, carbomer derivatives, acrylate, acrylamide, xanthan gum, carrageenan gum, aluminum silicate, silica, present in an amount of about 5% by weight It may comprise or consist of magnesium acid and cellulose derivatives.

  Suitable thickeners include hydroxyethyl acrylate, sodium acryloyldimethyltaurate copolymer, squalane, and polysorbate 60, for example from about 1% to about 10% or about 5% by weight based on the total weight of the composition. It can be included in or consist of, and is available as SIMUGEL NS® from SEPPIC, Fairfield, NJ. This thickener is a topical cosmetic composition as described herein, in combination with another thickener, such as cetyl alcohol, from about 0.5% to about 2% by weight based on the total weight of the composition. Or it may be used in an amount of about 2% by weight.

  One or more thickeners are present in the topical cosmetic composition from about 0.25% to about 15%, from about 1% to about 12%, or about 4% by weight based on the total weight of the composition. % To about 10%, about 5% to about 9% or about 7% by weight.

Free radical scavenger The described topical cosmetic composition can optionally further comprise an effective amount of a free radical scavenger. “Effective amount” means an amount that is sufficient to provide protection when applied properly, but not so great as to cause any side effects or adverse skin reactions, generally From about 0.1% to about 20%, or from about 1% to about 5%. Examples of such free radical scavengers include, but are not limited to, ascorbic acid (vitamin C) and salts and derivatives thereof (eg, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl palmitate, etc.), tocopherol (Vitamin E), tocopherol esters (eg, tocopheryl acetate, tocopheryl succinate, tocopheryl sorbate), butylated hydroxybenzoic acid and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2- Carboxylic acid (commercially available under the trade name TROLOX R®), gallic acid and its alkyl esters (propyl gallate), uric acid and its salts and alkyl esters, sorbic acid and its salts, ascorbyl esters of fatty acids , Amines (eg, N, N-diethylhydroxyamine, aminoguanidine), sulfhydryl compounds (eg, glutathione) and dihydroxyfumaric acid and salts thereof. In addition, catechins and polyphenols (eg, those found in green tea extracts) and flavonoids (eg, isoflavones, eg, genistein, and daidzein, flavones, chalcones, flavonones, coumarins, etc. found in soy extracts) may be used. .

Preservatives The described topical cosmetic compositions can optionally further comprise one or more preservatives. Suitable preservatives that may optionally be included in these compositions include, but are not limited to, one or more of propylene glycol, glycerol, butylene glycol, pentylene glycol, hexylene glycol, sorbitol, benzyl alcohol, and the like Derivatives of these and mixtures thereof, or may consist of them.

  In one embodiment, a suitable preservative may comprise or consist of one or more phenoxyethanol, methylisothiazolinone, phenoxyethanol, paraben, imidazolinidylurea and combinations thereof. Further, the preservative may be from about 0.05% to about 1.5%, from about 0.1% to about 1%, from about 0.1% to about 0.6%, based on the total weight of the composition. It may be present in an amount of wt%, or about 0.6 wt%. In other embodiments, suitable preservatives are phenoxyethanol and methylisothiazolinone, such as NEOLONE PE®, a formaldehyde-free broad-area fungicide based on methylisothiazolinone and phenoxyethanol, Rohm & It may comprise or consist of Haas, Philadelphia, PA.

Emulsifier The topical cosmetic composition may optionally further comprise one or more emulsifiers. Suitable emulsifiers that can be included in these compositions can include or consist of any of a wide variety of nonionic, cationic, anionic, zwitterionic and amphoteric emulsifiers.

  In this regard, suitable non-limiting examples of useful emulsifiers include one or more glycol esters, fatty acids, fatty acid alcohols, fatty acid glycol esters, fatty esters, fatty acid ethers, esters of glycerol, esters of propylene glycol, polyethylene Fatty acid ester of glycol, fatty acid ester of propylene glycol, ester of sorbitol, ester of sorbitan anhydride, carboxylic acid copolymer, ester and ether of glucose, ethoxylated ether, ethoxylated alcohol, alkyl phosphate, polyoxyethylene fatty ether phosphate, fatty acid Amides, acyl lactylates, soaps, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soybeans Roll, steareth-2, steareth-20, steareth-21, ceteares-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, cetyl phosphate, cetyl phosphate potassium, cetyl phosphate diethanolamine, polysorbate 60, stearin It may contain emulsifiers which may comprise or consist of glyceryl acid, PEG-100 stearate, derivatives thereof and mixtures thereof.

In one embodiment, the topical cosmetic compositions of the present invention comprise one or more C _14-22 alcohols and C _12-20 alkyl glucosides, or emulsifiers that may consist of them, such as fatty alcohols and alkyl glucosides. MONTANOV L (R) available from SEPPIC, Fairfield, NJ. Suitable emulsifiers may include one or more cetyl phosphates, alkyl phosphates, PEG100-glyceryl stearate and mixtures thereof, ethoxylated fatty acids in combination with fatty alcohols and / or glyceryl stearate and alkyl sulfates.

  In one embodiment, the topical cosmetic skin whitening composition of the present invention comprises from about 0.5% to about 10% by weight of emulsifier, from about 1% to about 5%, from about 1.% by weight based on the total weight of the composition. 5% to about 3.5%, or about 2% by weight of emulsifier can be included.

Humectant The topical cosmetic composition of the present invention may further comprise a humectant. Suitable non-limiting examples of wetting agents useful in the compositions of the present invention can include glycerin, butylene glycol, propylene glycol, sorbitol and triacetin.

Moisturizer The topical cosmetic composition may optionally further comprise one or more humectants. Suitable humectants include, but are not limited to, one or more of glycerin, pentylene glycol, butylene glycol, polyethylene glycol, sodium pyrrolidone carboxylate, alpha-hydroxy acid, beta-hydroxy acid, polyhydric alcohol, ethoxy It may comprise or consist of fluorinated and propoxylated polyols, polyols, polysaccharides, panthenol, hexylene glycol, propylene glycol, dipropylene glycol, sorbitol, derivatives thereof and mixtures thereof.

Suspending Agent The topical cosmetic composition of the present invention may further comprise a suspending agent. Non-limiting examples of suitable suspending agents useful in the compositions of the present invention include one or more alginic acid, bentonite, carbomer, carboxymethylcellulose and their salts, hydroxyethylcellulose, hydroxypropylcellulose, microcrystalline Cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, triglyceride, methylcellulose, polyoxyethylene fatty acid ester, polyvinylpyrrolidone, propylene glycol alginate, sodium alginate, sorbitan fatty acid ester, tragacanth And mixtures thereof.

Surfactant The topical cosmetic composition may optionally further comprise one or more surfactants. Suitable surfactants that can be included in these compositions can include or consist of one or more zwitterionic, amphoteric, anionic, cationic and nonionic surfactants and mixtures thereof. Suitable zwitterionic, amphoteric, anionic, cationic and nonionic surfactants are all McCutcheon's, Detergents and Emulsifiers, published by Allred Publishing Corporation, which is hereby incorporated by reference in its entirety. , North American Edition (1986) and McCutcheon's, Functional Materials, North American Edition (1992).

  Non-limiting examples of surfactants useful in the compositions of the present invention include nonionic surfactants, anionic surfactants, amphoteric surfactants, cationic surfactants and mixtures thereof.

  Non-limiting examples of amphoteric surfactants useful in the compositions of the present invention include alkylbetaines, alkylamidobetaines, aminopropionates, iminodipropionates, aminoglycinates, imidazolinium betaines, sulfobetaines and the like Selected from the group consisting of:

  Specific non-limiting examples of amphoteric surfactants useful in the compositions of the present invention include sodium 3-dodecylaminopropionate, sodium 3-dodecylaminopropanesulfonate, sodium lauroamphoacetate, cocodimethylcarboxymethylbetaine, Cocoamidopropyl betaine, cocobetaine, laurylamidopropyl betaine, oleyl betaine, lauryldimethylcarboxymethylbetaine, lauryldimethylalphacarboxyethylbetaine, cetyldimethylcarboxymethylbetaine, laurylbis (2-hydroxyethyl) carboxymethylbetaine, stearylbis- ( 2-hydroxypropyl) carboxymethylbetaine, oleyldimethylgamma-carboxypropylbetaine, laurylbis- (2-hydroxypropyl) a Selected from the group consisting of: carboxy-ethylbetaine, oleamidopropylbetaine, cocodimethylsulfopropylbetaine, stearyldimethylsulfopropylbetaine, lauryldimethylsulfoethylbetaine, laurylbis- (2-hydroxyethyl) sulfopropylbetaine and mixtures thereof Is.

  Similarly, non-limiting examples of anionic surfactants useful in the compositions of the present invention include alkyl sulfates, alkyl ethoxylated sulfates, beta-alkyloxyalkane sulfonates, alkyl ether sulfates, alkyl glyceryl ether sulfonates, alkyl ether carboxys. One selected from the group consisting of a rate, an acyl isethionate, an acyl sarcosinate, an acyl taurine, a succinate, an alkali metal, ammonium, or an alkanol ammonium salt thereof, and mixtures thereof.

  Specific non-limiting examples of anionic surfactants useful in the compositions of the present invention include ammonium lauryl sulfate, sodium lauryl sulfate, ammonium laureth sulfate, sodium laureth sulfate, alkyl glyceryl ether sulfonate, triethylamine lauryl sulfate, laureth sulfate Triethylamine, lauryl sulfate triethanolamine, laureth sulfate triethanolamine, lauryl sulfate monoethanolamine, laureth sulfate monoethanolamine, lauryl sulfate diethanolamine, laureth sulfate diethanolamine, sodium laurate monoglyceride sulfate, potassium lauryl sulfate, potassium laureth sulfate, lauryl sarcosine Acid sodium, sodium lauroyl sarcosinate, lauryl sarcosine, cocoyl sarcosine, cocoyl sulfate Ammonium, ammonium lauroyl sulfate, sodium cocoyl sulfate, sodium lauroyl sulfate, potassium cocoyl sulfate, potassium lauryl sulfate, lauryl sulfate triethanolamine, lauryl sulfate triethanolamine, cocoyl sulfate monoethanolamine, lauryl sulfate monoethanolamine, tridecylbenzenesulfonic acid Sodium, sodium dodecylbenzenesulfonate, sodium and ammonium salts of coconut alkyl triethylene glycol ether sulfate, tallow alkyl triethylene glycol ether sulfate, tallow alkyl hexaoxyethylene sulfate, disodium N-octadecyl sulfosuccinate, disodium lauryl sulfosuccinate, Diammonium lauryl sulfosuccinate, N- (1 2-dicarboxyethyl) -N-octadecylsulfosuccinate tetrasodium, sodium sulfosuccinate diamyl ester, sodium sulfosuccinate dihexyl ester, sodium sulfosuccinate dioctyl ester, doxate sodium and mixtures thereof Is.

  Specific non-limiting examples of cationic surfactants useful in the compositions of the present invention include behenyltrimethylammonium chloride, bis (acyloxyethyl) hydroxyethylmethylammonium mesosulfate, cetrimonium bromide, cetrimonium chloride, cetyltrimethyl Ammonium chloride, cocamidopropylamine oxide, distearyldimethylammonium chloride, ditarodimonium chloride, guahydroxypropyltrimonium chloride, rauralkonium chloride, lauryldimethylamine oxide, lauryldimethylbenzylammonium chloride, lauryl polyoxyethylenedimethylamine oxide , Lauryltrimethylammonium chloride, lautrimonium chloride, methyl-1-oleylamide Selected from the group consisting of ru-2-oleylimidazolinium methyl sulfate, picoline benzylammonium chloride, polyquaternium, stearalkonium chloride, stearyldimethylbenzylammonium chloride, stearyltrimethylammonium chloride, trimethylglycine and mixtures thereof Including things.

  Specific non-limiting examples of nonionic surfactants useful in the compositions of the present invention include polyoxyethylene fatty acid esters, sorbitan esters, cetyl octanoate, cocamide DEA, cocamide MEA, cocamide propyl dimethylamine. Oxide, coconut fatty acid diethanolamide, coconut fatty acid monoethanolamide, diglyceryl diisostearate, diglyceryl monoisostearate, diglyceryl monolaurate, diglyceryl monooleate, ethylene glycol distearate, ethylene glycol monostearate, ethoxylated castor oil Glyceryl monoisostearate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monooleate, glyceryl monostearate, tricaprylic acid / caprin Glyceryl, glyceryl triisostearate, glyceryl trioleate, glycol distearate, glycol monostearate, isooctyl stearate, lauramide DEA, lauric acid diethanolamide, lauric acid monoethanolamide, lauric acid / myristic acid diethanolamide, lauryldimethylamine Oxide, lauryl / myristylamide DEA, lauryl / myristyldimethylamine oxide, methyl gluces, methyl glucose sesquistearate, oleamide DEA, PEGyl distearate, polyoxyethylene butyl ether, polyoxyethylene cetyl ether, polyoxyethylene lauryl amine, polyoxyethylene Lauryl ester, polyoxyethylene lauryl ether, polyoxye Lennonyl phenyl ether, polyoxyethylene octyl ether, polyoxyethylene octyl phenyl ether, polyoxyethylene oleylamine, polyoxyethylene oleyl cetyl ether, polyoxyethylene oleyl ester, polyoxyethylene oleyl ether, polyoxyethylene stearylamine, polyoxy Ethylene stearyl ester, polyoxyethylene stearyl ether, polyoxyethylene tallowamine, polyoxyethylene tridecyl ether, propylene glycol monostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sesquiolein Sorbitan acid, sorbitan trioleate, stearamide DEA, steer Including those selected from the group consisting of phosphoric acid diethanolamide, stearic acid monoethanolamide, laureth-4 and mixtures thereof.

Vitamins The topical cosmetic composition of the present invention may optionally further comprise one or more vitamins or derivatives thereof. In one embodiment, the inventive topical cosmetic composition according to the invention of the invention described herein may comprise vitamin C and / or vitamin E. For example, vitamin C and / or vitamin E may be present in an amount effective to function as an antioxidant in the topical cosmetic composition of the present invention alone or in combination with other antioxidants. .

Penetration enhancer The topical cosmetic composition of the present invention may optionally further comprise one or more penetration enhancers. Non-limiting examples of suitable penetration enhancers include one or more hydrophilic solvents such as DMSO, DMF, DMA, glycerol, polyethylene glycol, pyrrolidone derivatives, N-decyl-methyl sulfoxide (Brij 36T), lower Alcohol fatty acids and / or esters, lipophilic accelerators such as decylazacycloheptan-2-one (Azone), ethyl acetate, ethyl propionate, liquid paraffin, lamonin, lard, hexadecyl alcohol, oleyl Alcohol, Hydroethyl lactamide, Solketal, Glycofural, Tetrahydro-furfuryl alcohol, Oleic acid, Isopropyl myristate, Lauryl alcohol, Miglyol oil, Linolenic acid, Lauric acid, Dodecyl-L-pyroglutamate And methyl laurate, surfactants such as anionic surfactants such as sodium lauryl sulfate, sodium dioctyl-sulfosuccinate, sorbitan monopalmitate, poloxamer, polyoxy-8-stearate, polyoxyethylene-o-oleyl- Ethers, long-chain alkyl sulfoxides, lauryl ethers, Brij 36T, cetyltrimethylammonium bromide and sodium oleate, sunscreens, for example octyl methoxycinnamate, oxybenzone, homosalate, octyl salicylate, padimate-o and slisobenzone, polymers, urea or the like Of permeation enhancers, which may comprise or be composed of derivatives of these, liposomes, and / or combinations thereof.

Perfume The topical cosmetic composition of the present invention may further comprise a perfume if desired. Suitable non-limiting examples of perfumes may include essential oils and blends such as perfume FAV22000 (BOUQUET® available from Firmenich) and any perfume.

Colorants The topical cosmetic compositions of the present invention may optionally further include a colorant including, but not limited to, one or more pigments, colorants, dyes, nano dyes, and / or combinations thereof.

  The dye may be present in the composition in an amount ranging from 0.01 to 25 wt% of the final composition, such as 3 to 10 wt%. It can be white or colored, inorganic or organic. Non-limiting examples include titanium oxide, zirconium oxide or cerium oxide, and zinc oxide, iron oxide or chromium oxide, ferric blue, chromium hydroxide, carbon black, ultramarine (aluminosilicate polysulfide), pyrophosphate Manganese and certain metal powders such as silver or aluminum are included. Other non-limiting examples include D & C dyes containing salts of calcium, barium, aluminum, strontium or zirconium that are commonly used to provide a makeup effect to the lips and skin.

  The fat-soluble or water-soluble pigment is present in the composition, alone or as a mixture, from 0.001 to 15 wt%, such as from 0.01 to 5 wt% or from 0.1 to 2 wt%, based on the total weight of the composition It can be present in an amount in the range of%. Non-limiting examples include Ponceau disodium salt, alizarin green disodium salt, quinoline yellow, amaranth trisodium salt, tetrazine disodium salt, rhodamine monosodium salt, fuchsin disodium salt, xanthophyll, methylene blue, carmine, Haloacids, azo and anthraquinone dyes, copper or iron sulfate, Sudan Brown, Sudan Red and Anato, and beetroot juice and carotene, and / or combinations thereof.

Other Embodiments In one embodiment, the described topical cosmetic composition optionally further comprises butylated hydroxytoluene, sodium metabisulfite, butylated hydroxyanisole, ascorbic acid and derivatives thereof, sulfites and derivatives thereof, At least one antioxidant, disodium edetate, EDTA, EDTA, which may comprise or consist of one or more components selected from the group consisting of esters, tocopheryl acetate and combinations thereof A chelating agent, glycol, silicon-containing emollient and comprising or consisting of one or more components selected from the group consisting of sodium, EDTA trisodium, EDTA tetrasodium and combinations thereof, and From their combination Emollient, acrylic acid copolymer, acrylic acid, acrylamide, polysorbate, fatty alcohol, gum, silicon, carbomer derivative, cellulose comprising or consisting of one or more components selected from the group consisting of A thickener, phenoxyethanol, methylisothiazolinone, phenoxyethanol, paraben, imidazolylnidylurea, which may comprise or consist of one or more components selected from the group consisting of derivatives and combinations thereof, and From the group consisting of preservatives, triethanolamine, aminomethylpropanol, sodium hydroxide and combinations thereof, which may comprise or consist of one or more components selected from the group consisting of combinations thereof Selected It contains a species or more components, or may be composed of them, pH adjusting agents, as well as C _{14 to 22} alcohols, one or more selected from C _{12 to 20} alkyl glucosides, and combinations thereof It may contain at least one emulsifier that may comprise or consist of components.

  In other embodiments, the invention provides that the emollient is a propylene glycol, glycerin, butylene glycol, pentylene glycol, cyclopentasiloxane, dimethicone crosspolymer, cyclopentasiloxane PEG / PPG-18 / 18 dimethicone and combinations thereof. One or more components selected from the group consisting of or consisting of and / or a thickener comprising hydroxyethyl acrylate, sodium acryloyldimethyltaurate copolymer, squalane, polysorbate 60, Carbomer derivatives, xanthan gum, carrageenan gum, aluminum silicate, magnesium silicate, cellulose derivatives, cetyl alcohol, stearyl alcohol, cetyl and stearyl alcohol, stearic acid Or comprising one or more components selected from Riseriru, and combinations thereof, or can be constructed from them, it relates to topical cosmetic compositions.

Topical formulations In one embodiment, the topical cosmetic composition of the present invention comprises a serum, gel cream, lotion, cream, ointment, gel, aerosol, foam, foaming liquid, solution (solubilizing system), paste, suspension. Suspension, dispersion, emulsion, skin cleanser, milk, mask, solid bar, bar (eg bar soap), encapsulated formulation, microencapsulated formulation, microparticle or nanoparticle or vesicle dispersion, or other Formulated into a cosmetically acceptable topical dosage form. In the case of a vesicle dispersion, the lipids that form the vesicles may be ionic or non-ionic or mixtures thereof. Formulations can include one or more aqueous and / or anhydrous formulations.

  In another embodiment, the inventive topical cosmetic composition according to the invention described herein may comprise or consist of an anhydrous formulation, an aqueous formulation or an emulsion.

  In yet another embodiment, the inventive topical cosmetic composition according to the invention described herein is formulated in a serum or gel cream.

Optional additional active agents The topical cosmetic compositions described herein may optionally further comprise one or more cosmetic or dermatological active agents in addition to the described skin lightening actives. Such agents include, for example, additional skin lightening actives, including plant-derived and non-plant-derived skin lightening agents, such as pigmentation inhibitors, tyrosinase inhibitors, and / or melanogenesis inhibitors of melanocytes. And / or non-skin whitening actives such as fluorescent whitening agents, sunscreens, anti-inflammatory agents, antibacterial agents, antifungal agents, anti-wrinkle agents, anti-atrophy agents, anti-acne agents, free radical scavengers, keratins Solubilizer, vitamin, anti-elastase and / or anti-collagenase agent, peptide, fatty acid derivative, steroid, trace element, algae and / or plankton extract, enzyme and / or coenzyme, flavonoid and / or ceramide, α-hydroxy acid As well as combinations thereof.

Additional skin lightening actives The topical cosmetic composition may optionally further contain one or more additional skin lightening agents. Suitable additional skin lightening agents include, but are not limited to, one or more ginkgo biloba extract, carob bean extract, age extract, geranium herb extract, perilla extract, cinnamon extract, sweet marjoram extract , Rabbit extract, Concha Blanca extract, Colladecabaro, Pyri-Pyri, Pinon Negro, Pinon Blanco, Clove extract, Alfalfa, Baliosperumum tantanum, Neemdan, Convolvulus arvenis, Gayo, Sansonin, Syuronin Hakusempi, Woodford fructosa, Great crested beetle, passiflorine, tepezcohite, amoule, Hobiyu, B ffalo uri, Achote, Guayule, Adatoda, citronella, Desmodium gangeticum, Nan Takayama Shaw, Smilax zeylanica, Gastrodia elata, Karukeija, microphylla, and Acer buergerianm, Kichiascoporia, Arecatachu, leaves of black bamboo, Atractylodes, Koidzumi, Tila, Camotede azafran, Jamaica, Poleo verde, Navo It may include or consist of negro, cypress, licorice, banquet, karojitsu, calocon, Dioscorea physoma and Aquilaria.

  Still other skin lightening agents include, but are not limited to, one or more of teprenone, dihydroxy-isoquinoline, indomethacin, 3-hydroxymanure, vitamin K (eg, vitamins K1-K7, homologs thereof) , Salts and derivatives), thiazolidinone derivatives and kynurenine and derivatives and salts thereof, retinol and derivatives thereof (eg tretinoin, retinoic acid), resorcinol and derivatives thereof (eg 4-alkylresorcinol etc.), resveratrol, Placental extracts, ellagic acid, linoleic acid and α-lipoic acid, and aminophenols such as those described in US Pat. No. 6,203,781 (Formula 1) can be included or configured. The amount of additional skin lightening agent generally ranges from about 0.01% to about 20% based on the total weight of the composition. A suitable additional skin lightening agent is α-lipoic acid.

The cosmetic composition according to the invention may optionally comprise a pigmentation inhibitor. Examples of specific pigmentation inhibitors include, but are not limited to, p-aminobenzoic acid derivatives, salicylic acid derivatives, benzenesulfonamide derivatives, imidazole derivatives, naphthalene derivatives, hydroxyanthranilic acid or their salts and their Derivatives, anthranilic acid derivatives, coumarin derivatives, amino acid derivatives (eg 2-amino-3- [1-carboxyl-2- (1H-imidazol-4-yl) ethyl] aminobutanoic acid, 2-amino-3- [1- Carboxyl-2- (1H-imidazol-4-yl) ethyl] aminobutane hydrochloride, 2-amino-3- [1-carboxyl-2- (1H-imidazol-4-yl) ethyl] aminobutanoic acid sodium salt and 2- Amino-3- [1-carboxyl-2- (1H-imidazol-4-y ) Ethyl] aminobutanoic acid potassium salt), benzotriazole derivatives, tetrazole derivatives, imidazoline derivatives, pyrimidine derivatives, dioxane derivatives, camphor derivatives, furan derivatives, pyrone derivatives, nucleic acid derivatives, allantoin derivatives, nicotinic acid derivatives, ascorbic acid or their salts And derivatives thereof (for example, magnesium L-ascorbate phosphate, ascorbyl palmitate, ascorbyl dipalmitate, hydroxyproline phosphate ascorbate, 5-o-alpha-D-glucopyranosyl-L-ascorbic acid, L-ascorbic acid) Acid phosphate sodium salt, L-ascorbic acid phosphate potassium salt, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphate ester Calcium salt, L-ascorbic acid phosphate aluminum salt, L-ascorbic acid sulfate sodium salt, L-ascorbic acid sulfate potassium salt, L-ascorbic acid sulfate magnesium salt, L-ascorbic acid sulfate calcium salt, L -Ascorbic acid sulfate aluminum salt, L-ascorbic acid sodium salt, L-ascorbic acid potassium salt, L-ascorbic acid magnesium salt, L-ascorbic acid calcium salt, L-ascorbic acid aluminum salt, 6-o-alpha-D -Galactopyranosyl-L-ascorbic acid, 2-o-beta-D-galactopyranosyl-L-ascorbic acid, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphate sodium salt, L − Ascorbic acid sulfate sodium salt, 6-o-acyl ascorbic acid phosphate sodium salt, 6-o-acyl ascorbic acid phosphate ammonium salt, 6-o-acyl ascorbic acid phosphate isopropanolamine salt, 3-o -Isopropyl-L-ascorbic acid, 6-o-alkylascorbic acid phosphate potassium salt, 6-o-alkylascorbic acid phosphate calcium salt, 6-o-alkylascorbic acid phosphate barium salt, 6-o -Alkylascorbic acid phosphate ammonium salt, 6-o-alkylascorbic acid phosphate monoethanolamine salt, 6-o-alkylascorbic acid phosphate diethanolamine salt, 6-o-alkylascorbic acid phosphate ester Tertriethanolamine salt, 6-o-alkylascorbic acid phosphate monoisopropanolamine salt, 6-o-alkylascorbic acid phosphate diisopropanolamine salt, 6-o-alkylascorbic acid phosphate triisopropanolamine salt 3-o-glycosyl-L-ascorbic acid, 6-o-beta-D-galactopyranosyl-L-ascorbic acid, ascorbic acid phosphate cholesterol ester, palmitic acid-L-ascorbyl, isopalmitic acid-L- Ascorbyl, dipalmitic acid-L-ascorbyl, diisopalmitic acid-L-ascorbyl, stearic acid-L-ascorbyl, isostearic acid-L-ascorbyl, distearic acid-L-ascorbyl, diisostearic acid-L-asco Bill, myristic acid-L-ascorbyl, isomyristic acid-L-ascorbyl, dimyristic acid-L-ascorbyl, diisomyristic acid-L-ascorbyl, 2-ethylhexanoic acid-L-ascorbyl, di-2-ethylhexane Acid-L-ascorbyl, oleic acid-L-ascorbic acid, 2-o-alpha-D-glucosyl-L-ascorbic acid, 2-o-alpha-D-maltosyl-L-ascorbic acid, 2-o-alpha- D-maltotriosyl-L-ascorbic acid, 3-o-alpha-D-glycosyl-L-ascorbic acid, 2-o-alpha-D-maltosyl-L-ascorbic acid, 2-o-alpha-D-malto Triosyl-L-ascorbic acid, L-ascorbic acid tetraisopalmitate, L-ascorbic acid Tetralauric acid ester, L-ascorbic acid tetra-2-ethylhexanoic acid ester, L-ascorbic acid tetraoleic acid ester, 5,6-isopropylidene-L-ascorbic acid, L-ascorbic acid retinol ester, L-ascorbic acid -DL-tocopherol phosphate, L-3-o-ethylascorbic acid, L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, L-ascorbic acid trioleate, ascorbic acid triphosphate, 2-o Ascorbyl cinnamate, 2-o-ascorbyl ferrate, 2-o-ascorbyl caffeate, 2-o-ascorbyl cinnamate, 2-o- [6-palmitoyl ascorbyl] -4'-acetoxyferrate, DL-alpha -Tokov Errol-2-L-ascorbic acid phosphoric diester, ascorbic acid inositol binding derivative, ascorbic acid phosphoramide derivative, ascorbyl arbutin conjugate, ascorbyl-phosphoryl-cholesterol, chromanyl ascorbic acid derivative and ascorbic acid / sialic acid derivative), tocopherol Or salts thereof and derivatives thereof (e.g., alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, epsilon-tocopherol, alpha-tocopheryl retinoate, aminomethylated tocopherol, hydroxymethylated tocopherol, tocopheryl phosphorus Acid ester, tocopherol acetate, tocopherol nicotinate, tocopherol succinate, tocopher Allulinolate, tocopherol orotate, DL-alpha-tocopheryl glucoside, DL-alpha-tocopheryl maltoside, DL-beta-tocopheryl glucoside, DL-beta-tocopheryl maltoside, DL-gamma-tocopheryl glucoside, DL- Gamma-tocopheryl maltoside, DL-delta-tocopheryl glucoside, DL-delta-tocopheryl maltoside, D-alpha-tocopheryl glucoside, D-alpha-tocopheryl maltoside, D-beta-tocopheryl glucoside, D -Beta-tocopheryl maltoside, D-gamma-tocopheryl glucoside, D-gamma-tocopheryl maltoside, D-delta-tocopheryl glucoside, D-delta-tocopheryl maltoside, L-alpha-tocofe L-glucoside, L-alpha-tocopheryl maltoside, L-beta-tocopheryl glucoside, L-beta-tocopheryl maltoside, L-gamma-tocopheryl glucoside, L-gamma-tocopheryl maltoside, L-delta- Tocopheryl glucoside, L-delta-tocopheryl maltoside, 1- (sulfoethylamino) -3- (alpha-tocopheryl-6-yloxy) propan-2-ol, 1- (carboxypropylamino) -3- (alpha -Tocopheryl-6-yloxy) propan-2-ol hydrochloride, S- [3- (alpha-tocopheryl-6-yloxy) -2-hydroxypropyl] cysteine, S- [3- (alpha-tocopheryl-6-yloxy) ) -2-Hydroxypropyl] -gamma-glutamyl system Inylglycine, N- [3- (alpha-tocopheryl-6-yloxy) -2-hydroxypropyl] aspartic acid and N- [3- (alpha-tocopheryl-6-yloxy) -2-hydroxypropyl] glutamic acid), tocotrienol or Salts thereof and derivatives thereof (eg alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, tocotrienol acetate, tocotrienol nicotinate, tocotrienol succinate, tocotrienol linoleate, tocotrienol orotate), kojic acid or its Derivatives such as 2-methoxymethyl-hydroxy-4H-pyran-4-one, 2-ethoxymethyl-5-hydroxy-4H-pyran-4- 2-benzoyloxymethyl-5-hydroxy-4H-pyran-4-one, 2-cinnamoyloxymethyl-5-hydroxy-4H-pyran-4-one, 2-phenoxymethyl-5-hydroxy-4H -Pyran-4-one, kojic acid glycoside, geranylacetone, kojic acid monobutyrate, kojic acid monocaprate, kojic acid monopalmitate, kojic acid monostearate, kojic acid monocinnamate, kojic acid monobenzoate, kojic acid dibutyrate , Kojic acid dipalmitate, kojic acid distearate and kojic acid dioleate), oxybenzone, benzophenone, guaiazulene, shikonin, baicalin or salts thereof and derivatives thereof, baicalein or salts thereof and derivatives thereof, berberine or derivatives thereof Salts and derivatives thereof, chrysin or salts thereof and derivatives thereof, apigenin or salts thereof and derivatives thereof, luteolin or salts thereof and derivatives thereof, acacetin or salts thereof and derivatives thereof, diosmethine or salts thereof and derivatives thereof Kaempferol or a salt thereof and derivatives thereof, trifolin or a salt thereof and derivatives thereof, astragalin or a salt thereof and derivatives thereof, quercetin or a salt thereof and derivatives thereof, quercitrin or a salt thereof and derivatives thereof, Ercitrin or a salt thereof and derivatives thereof, rutin or a salt thereof and derivatives thereof, morin or a salt thereof and derivatives thereof, myricetin or a salt thereof and derivatives thereof, myricitrin Or salts thereof and derivatives thereof, dachiscetin or salts thereof and derivatives thereof, quercetagetin or salts thereof and derivatives thereof, isorhamnetin or salts thereof and derivatives thereof, pinocembrin or salts thereof and derivatives thereof, naringenin or salts thereof and the like Derivatives, hesperetin or its salts and their derivatives, eriodictyol or its salts and their derivatives, pinobankin or its salts and their derivatives, aromadendrine or its salts and their derivatives, angeletine or its salts and their Derivatives, taxifolin or a salt thereof and derivatives thereof, astilbine or a salt thereof and derivatives thereof, amperopsin or a salt thereof and derivatives thereof, Spiraeosi Kaempferol-7-neohesperidoside, glutathione or its salts and derivatives thereof, isoflavone glycosides (for example, 6-o-apiosyl puerarin-4'-o-glucoside, 6-o-glucosyl puerarin, 3'- Hydroxypuerarin-4′-o-glucoside and 6-o-apiosyl-3′-hydroxypuerarin), gamma-pyrone glucoside (eg, maltol-3-o- (6′-o-apiosyl) -glucoside and maltol-3 -O- (6'-o-apiosyl) -glucoside), isononyl ferrate, ellagic acid or a salt thereof and derivatives thereof (for example, 5,4-dimethylellagic acid, 3,3'-dimethylellagic acid, 3 , 3 ′, 4-trimethylellagic acid, 3,3 ′, 4,4′-tetramethyl-5-methoxyellagic acid 3-ethyl-4-methyl-5-hydroxyellagic acid and amritoside), lucinol, ondisaponin, bacmond saponin, ruscogenin, sericoside, asiaticoside, hederin, senegin, benzoic acid anilides (eg, 4-hydroxy-N -(2-hydroxyphenyl) benzoic acid amide, 4-hydroxy-N- (3-hydroxyphenyl) benzamide, 4-hydroxy-N- (4-hydroxyphenyl) benzamide, 3,5-di-t-butyl-4 -Hydroxy-N- (4-hydroxyphenyl) benzamide, 3,5-di-tert-butyl-4-hydroxy-N- (3-hydroxyphenyl) benzamide and 3,5-di-tert-butyl-4-hydroxy -N- (2-hydroxyphenyl) benzamide), diphenylpi Phosphorus, Cyproheptadine, Triprolidine, Dimethindene, Ozagrel, Isotipendil, Iproheptin, Homochlorcyclidine, Alimemazine, Bucillamine, Ochitosamide, Vidarabine, Xanthoxol, Phenylmercury hexachlorophene, Mercuric oxide, Mercury chloride, Hydrogen peroxide Water, zinc peroxide, placenta extract (eg, bovine placenta, porcine placenta, horse placenta and sheep placenta), almond (BIAN TAO) extract, fennel leaf extract, lobster extract, okera extract , Konfuyo extract, Uncaria extract, Gejicha extract, Gypsum extract, Licorice extract, Gardenia extract (ZHI ZI) extract, Kuranigean extract, Clara extract, Koganebana (HUANG QIN) extract, Wheat (wheat) extract Extract, Rice (rice) extract, Koreaia extract, Sidwaya extract, Sankyu extract, Sanvitro extract, Sunpens extract, Silane (BAIJI) extract, Senkyu (CHUAN XIONG) extract, Senna extract, Sempukuka extract, Senktsusai extract, Surigatin extract, QIAN HU extract, Yi YI REN extract, Clam extract, MAN JING ZI extract, Hamamelis extract, Palm extract , Parietalia extract, safflower (HONG HUA) extract, MANG (SANG BAI PI) extract, malvanojadine (KU SHEN) extract, purple squirrel extract, white vanilla squirrel extract, mugwort worm extract, Yashajitsu extract, Hong Kong extract Goods ) Extract, Yuzuriha extract, Yakoutou extract, and Fatsia Japonica extract.

The cosmetic composition according to the present invention may contain a tyrosinase inhibitor. Specific examples of tyrosinase inhibitors include ascorbic acid or a salt thereof and derivatives thereof (for example, magnesium L-ascorbate phosphate, ascorbyl palmitate, ascorbyl dipalmitate, hydroxyprophosphate phosphate ascorbate, 5-o-alpha -D-glucopyranosyl-L-ascorbic acid, L-ascorbic acid phosphate sodium salt, L-ascorbic acid phosphate potassium salt, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphate calcium salt, L-ascorbic acid phosphate aluminum salt, L-ascorbic acid sulfate sodium salt, L-ascorbic acid sulfate potassium salt, L-ascorbic acid sulfate magnesium salt, L-ascorbine Sulfate calcium salt, L-ascorbic acid sulfate aluminum salt, L-ascorbic acid sodium salt, L-ascorbic acid potassium salt, L-ascorbic acid magnesium salt, L-ascorbic acid calcium salt, L-ascorbic acid aluminum salt, 6 -O-alpha-D-galactopyranosyl-L-ascorbic acid, 2-o-beta-D-galactopyranosyl-L-ascorbic acid, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphorus Acid ester sodium salt, L-ascorbic acid sulfate sodium salt, 6-o-acyl ascorbic acid phosphoric acid ester sodium salt, 6-o-acyl ascorbic acid phosphoric acid ester ammonium salt, 6-o-acyl ascorbic acid phosphoric acid ester Isopropano Amine salt, 3-o-isopropyl-L-ascorbic acid, 6-o-alkylascorbic acid phosphate potassium salt, 6-o-alkylascorbic acid phosphate calcium salt, 6-o-alkylascorbic acid phosphate Barium salt, 6-o-alkylascorbic acid phosphate ammonium salt, 6-o-alkylascorbic acid phosphate monoethanolamine salt, 6-o-alkylascorbic acid phosphate diethanolamine salt, 6-o-alkylascorbine Acid phosphate ester triethanolamine salt, 6-o-alkylascorbic acid phosphate monoisopropanolamine salt, 6-o-alkylascorbic acid phosphate diisopropanolamine salt, 6-o-alkylascorbic acid phosphate Ester triisopropanolamine salt, 3-o-glycosyl-L-ascorbic acid, 6-o-beta-D-galactopyranosyl-L-ascorbic acid, ascorbic acid phosphate cholesterol ester, palmitic acid-L-ascorbyl, iso Palmitic acid-L-ascorbyl, dipalmitic acid-L-ascorbyl, diisopalmitic acid-L-ascorbyl, stearic acid-L-ascorbyl, isostearic acid-L-ascorbyl, distearic acid-L-ascorbyl, diisostearic acid-L- Ascorbyl, myristic acid-L-ascorbyl, isomyristic acid-L-ascorbyl, dimyristic acid-L-ascorbyl, diisomyristic acid-L-ascorbyl, 2-ethylhexanoic acid-L-ascorbyl, di-2-ethylhexane acid L-ascorbyl, oleic acid-L-ascorbic acid, 2-o-alpha-D-glucosyl-L-ascorbic acid, 2-o-alpha-D-maltosyl-L-ascorbic acid, 2-o-alpha-D- Maltotriosyl-L-ascorbic acid, 3-o-alpha-D-glucosyl-L-ascorbic acid, 2-o-alpha-D-maltosyl-L-ascorbic acid, 2-o-alpha-D-maltotriosyl -L-ascorbic acid, L-ascorbic acid tetraisopalmitate, L-ascorbic acid tetralaurate, L-ascorbic acid tetra-2-ethylhexanoate, L-ascorbic acid tetraoleate, 5,6 -Isopropylidene-L-ascorbic acid, L-ascorbic acid retinol ester, -Ascorbic acid-DL-tocopherol phosphate ester, L-3-o-ethylascorbic acid, L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, L-ascorbic acid trioleate, ascorbic acid triphosphate ester, 2-o-ascorbyl cinnamate, 2-o-ascorbyl ferrate, 2-o-ascorbyl caffeate, 2-o-ascorbyl synapate, 2-o- [6-palmitoyl ascorbyl] -4'-acetoxyferrate, DL-alpha-tocopherol-2-L-ascorbic acid phosphoric acid diester, ascorbic acid inositol-conjugated derivative, ascorbic acid phosphoramide derivative, ascorbic acid arbutin conjugate, ascorbyl-phosphoryl-cholesterol, chromanyl asco Binic acid derivatives and ascorbic acid sialic acid derivatives), kojic acid or its salts and their derivatives (eg 2-methoxymethyl-hydroxy-4H-pyran-4-one, 2-ethoxymethyl-5-hydroxy-4H-pyran -4-one, 2-benzoluyloxymethyl-5-hydroxy-4H-pyran-4-one, 2-cinnamoyloxymethyl-5-hydroxy-4H-pyran-4-one, 2-phenoxymethyl-5- Hydroxy-4H-pyran-4-one, kojic acid glycoside, geranylacetone, kojic acid monobutyrate, kojic acid monocaprate, kojic acid monopalmitate, kojic acid monostearate, kojic acid monocinnamate, kojic acid monobenzoate, kojji Acid dibutyrate, kojic acid dipalmitate, kojic acid dis Tearates and kojic acid dioleates), tocopherols or their salts and their derivatives (eg alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, epsilon-tocopherol, alpha-tocopheryl retinoate, aminomethylated tocopherol, hydroxy Methylated tocopherol, tocopheryl phosphate, tocopherol acetate, tocopherol nicotinate, tocopherol succinate, tocopherol linoleate, tocopherol orotate, DL-alpha-tocopheryl glucoside, DL-alpha-tocopheryl maltoside, DL-beta- Tocopheryl glucoside, DL-beta-tocopheryl maltoside, DL-gamma-tocopheryl Coside, DL-gamma-tocopheryl maltoside, DL-delta-tocopheryl glucoside, DL-delta-tocopheryl maltoside, D-alpha-tocopheryl glucoside, D-alpha-tocopheryl maltoside, D-beta-toco Ferryl glucoside, D-beta-tocopheryl maltoside, D-gamma-tocopheryl glucoside, D-gamma-tocopheryl maltoside, D-delta-tocopheryl glucoside, D-delta-tocopheryl maltoside, L-alpha- Tocopheryl glucoside, L-alpha-tocopheryl maltoside, L-beta-tocopheryl glucoside, L-beta-tocopheryl maltoside, L-gamma-tocopheryl glucoside, L-gamma-tocopheryl maltoside, L-delta -Tocopheryl gluco L-delta-tocopheryl maltoside, L- (sulfoethylamino) -3- (alpha-tocopheryl-6-yloxy) propan-2-ol, 1- (carboxypropylamino) -3- (alpha-tocopheryl) -6-yloxy) propan-2-ol hydrochloride, S- [3- (alpha-tocopheryl-6-yloxy) -2-hydroxypropyl] cysteine, S- [3- (alpha-tocopheryl-6-yloxy)- 2-hydroxypropyl] -gamma-glutamylcysteinylglycine, N- [3- (alpha-tocopheryl-6-yloxy) -2-hydroxypropyl] aspartic acid, and N- [3- (alpha-tocopheryl-6- Yloxy) -2-hydroxypropyl] glutamic acid), tocotrienol Or salts thereof and derivatives thereof (e.g., alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, tocotrienol acetate, tocotrienol nicotinate, tocotrienol succinate, tocotrienol linoleate and tocotrienol orotate), N-acetyl Tyrosine or a salt thereof and derivatives thereof, glutathione or a salt thereof and derivatives thereof, ellagic acid or a salt thereof and derivatives thereof (for example, 3,4-dimethylellagic acid, 3,3′-dimethylellagic acid, 3,3 ', 4-trimethylellagic acid, 3,3', 4,4'-tetramethyl-5-methoxyellagic acid, 3-ethyl-4-methyl-5-hydroxyellagic acid and amritoside), isonitrine A , Isonitrine B, isonitrine C, isonitrine D, isonitrinic acid E, isonitrinic acid F, dermadein, tricobilidein, and other isonitrile antibiotics, orselinic acid derivatives (for example, orthoric acid, orthoric acid ethyl ester orcinol, p-geranylorselin) Acid, p-geranylorceric acid ethyl ester geranylorcinol, p-farnesylorceric acid, p-farnesylorceric acid ethylester farnesylorcinol, p-dodecanylorceric acid, p-dodecanylorceric acid ethylester Dodecanylorcinol, p-tetradecanylorceric acid, p-tetradecanylorceric acid ethyl ester tetradecanylorcinol, p-hexadecanylorceric acid, p-hexadecanylorserine Ethyl ester hexadecanylorcinol, p-undecanylorceric acid, p-undecanylorceric acid ethyl ester undecanylorcinol, p-tridecanylorceric acid, p-tridecanylorceric acid ethyl Ester undecanylorcinol, p-pentadecanylorceric acid, p-pentadecanylorceric acid ethyl ester pentadecanylorcinol, ethylhexylorselinic acid, p-ethylhexylorceric acid ethylester ethylhexylorcinol, p- Cyclohexylmethylorceric acid, p-cyclohexylmethylorceric acid ethyl ester cyclohexylmethylorcinol, p-hydroxyethylhexylorceric acid methyl ester and p-hydroxyethylhexylorselic acid Droxyethylhexylorcinol), umbelic acid, brefeldin, oxydesveratrol, resorcinol derivative (4-cyclohexylresorcinol), 3-hydroxyketone compound (for example, 1,5-bis (p-hydroxyphenyl) -2- Hydroxypentan-4-one and 1,5-bis (o, p-dihydroxyphenyl) -2-hydroxypentan-4-one and 1,5-bis (p-hydroxyphenyl-m-methoxyphenyl) -2-hydroxy Pentane-4-one), 1,3-diketone compounds (for example, 1,5-bis (p-hydroxyphenyl) -2,4-pentanedione, 1,5-bis (o, p-dihydroxyphenyl) -2 , 4-pentanedione and 1,5-bis (p-hydroxyphenyl-m-methoxy Phenyl) -2,4-pentanedione), bishydroxybenzylamide, gamma-aminobutyric acid or derivatives thereof (eg, N-methyl-gamma-aminobutyric acid, N-dimethyl-gamma-aminobutyric acid, and oleyl gamma-aminobutyric acid) Esters), Hydrogen peroxide, Zinc peroxide, Placenta extract, Lucinol, Silk extract, Acacia extract, Acerola extract, Semen Abutili extract, Weeping birch extract, Quels (MO SHI ZI, Kuritabachi) extract Extract, chestnut extract, tortoise extract, clover bean extract, tomato extract (dried), seri extract, buckwheat extract, dabilia extract, nazuna extract, Fujiba kama (dry) extract, chamomile extract, mulberry extract , Gardenia extract, toki extract, bitumen Extracts, Clara extract, mugwort extract, honeysuckle extract, yellowfin extract, dolphin extract, pine pod extract, pearl extract, nettle extract, hop extract, hawthorn extract, eucalyptus extract, yarrow extract , Altea extract, GUI PI (Nikkei bark, Cinnamomi Cortex) extract, MAN JING ZI (Mancai fruit) extract, Hamamelis extract, Yamaguchi extract, bellflower extract, TU SI ZI (Nenshika Zura seed) Extract, HSU SUI TZU (Hortho Seed) extract, SHE GAN (Hypergi) extract, MA HUANG (Ephedra Herba) extract, CHUAN XIONG (Cenii Rhizoma) extract DU HUO (Udo roots and rhizomes) extract, CHAI HU (Mishima psycho root, Bupleuri Radix) extract, FANG FENG (Bow Fu root, Saposnikoviae Radix) extract, BEI SHA SH i (Hamabo h , HUANG QIN (Scutellariae Radix) extract, MU DAN PI (Botpi root, Moutan Cortex) extract, SHAO YAO (Peonies root, Paeoniae Radix) extract, Gennoshoco G extract Root, Puerariae Radix extract, WU BEI ZI (Gallah Rhois) extract, Aloe extract, SHENG MA (Shoma's Root, Cimicifugae Rhizoma) extract, HONG HUA (Safflower Flower, Carthami Flos) extract, green tea extract, black tea extract, asen drug extract.

The cosmetic composition according to the present invention may contain a melanocyte melanogenesis inhibitor. Specific examples of melanocyte inhibitors include lobeline or lobeline derivatives, liquiritin derivatives (eg, liquiritin-alpha-glucoside and liquiritin-alpha-maltoside), phenylchroman derivatives, chromone derivatives (eg, 2-butylchromone, 2-pentylchromone, 2-heptylchromone, 2-nonylchromone, 2-hexadecylchromone, 2- (1-ethylpentyl) chromone, 2-butyl-7-methoxychromone, 2-pentyl-7-methoxychromone, 2- Heptyl-7-methoxychromone, 2-nonyl-7-methoxychromone, 2-pentadecyl-7-methoxychromone, 2- (1-ethylpentyl) -7-methoxychromone, 7-hydroxy-2-methylchromone, 7- Hydroxy-2-bu Lucromone, 7-hydroxy-2-pentylchromone, 7-hydroxy-2-heptylchromone, 7-hydroxy-2-nonylchromone, 7-hydroxy-2-pentadecylchromone, and 7-hydroxy-2- (1-ethylpentyl) ) Chromone), azelaic acid derivatives (eg azelaic acid monoalkyl esters and azelaic acid dialkyl esters), phosphatidylglucosamine, lysophosphatidylglucosamine, 3-beta-D-glucopyranosyl manur, 3-beta-D-maltopyrano Silmanur, substituted amino acid derivatives (eg, DL-N-formyl-3- (1-naphthyl) alanine, DL-N-acetyl-3- (1-naphthyl) alanine, DL-N-propionyl-3- (1- Naphthyl) alanine, DL-N-bu Ril-3- (1-naphthyl) alanine, DL-N-isobutyryl-3- (1-naphthyl) alanine, DL-N-valeryl-3- (1-naphthyl) alanine, DL-N-isovaleryl-3- ( 1-naphthyl) alanine, DL-N- (2-methylvaleryl) -3- (1-naphthyl) alanine, DL-N- (3-methylvaleryl) -3- (1-naphthyl) alanine, DL-N- (4 -Methylvaleryl) -3- (1-naphthyl) alanine, DL-Nt-butylacetyl-3- (1-naphthyl) alanine, DL-N-pivaloyl-3- (1-naphthyl) alanine, DL-N- Caproyl-3- (1-naphthyl) alanine, DL-N- (2-ethylhexanoyl) -3- (1-naphthyl) alanine, DL-N- (2-methylhexanoyl) -3- (1- Naphthyl) alanine, DL-N-heptanoyl-3- (1-naphthyl) alanine, DL-N-octanoyl-3- (1-naphthyl) alanine, DL-N- (2-propylpentanoyl) -3- (1 -Naphthyl) alanine, DL-N-nonanoyl-3- (1-naphthyl) alanine, DL-N-decanoyl-3- (1-naphthyl) alanine, DL-N-undecanoyl-3- (1-naphthyl) alanine, DL-N-dodecanoyl-3- (1-naphthyl) alanine, DL-N-tridecanoyl-3- (1-naphthyl) alanine, DL-N-tetradecanoyl-3- (1-naphthyl) alanine, DL-N -Pentadecanoyl-3- (1-naphthyl) alanine, DL-N-hexadecanoyl-3- (1-naphthyl) alanine, DL-N-heptadecanoy -3- (1-naphthyl) alanine, DL-N-octadecanoyl-3- (1-naphthyl) alanine, DL-N-nonadecanoyl-DL-3- (1-naphthyl) alanine, DL-N-icosanoyl- 3- (1-naphthyl) alanine, DL-N-acryloyl-3- (1-naphthyl) alanine, DL-N-crotoniloyl-3- (1-naphthyl) alanine, DL-N-methacryloyl-3- (1- Naphthyl) alanine, DL-N-vinylacetyl-3- (1-naphthyl) alanine, DL-N-cyclopropanoyl-3- (1-naphthyl) alanine, DL-N- (2-pentenoyl) -3- ( 1-naphthyl) alanine, DL-N- (4-pentenoyl) -3- (1-naphthyl) alanine, DL-N- (2-hexenoyl) -3- (1-naphthyl) a Nin, DL-N- (3-hexenoyl) -3- (1-naphthyl) alanine, DL-N- (2-methyl-3-pentenoyl) -3- (1-naphthyl) alanine, DL-N-cyclohexe Noyl-3- (1-naphthyl) alanine, DL-N- (10-undecenoyl) -3- (1-naphthyl) alanine, DL-N-linoleyl-3- (1-naphthyl) alanine, DL-N-hydroxy Acetyl-3- (1-naphthyl) alanine, DL-N- (6-hydroxycaproyl) -3- (1-naphthyl) alanine, DL-N- (8-hydroxyoctanoyl) -3- (1-naphthyl) ) Alanine, DL-N- (9-hydroxynonanoyl) -3- (1-naphthyl) alanine, DL-N- (10-hydroxydecanoyl) -3- (1-naphthyl) alanine, D L-N- (11-hydroxyundecanoyl) -3- (1-naphthyl) alanine, DL-N- (12-hydroxydecanoyl) -3- (1-naphthyl) alanine, DL-N-benzoyl-3 -(1-naphthyl) alanine, DL-N- (2-hydroxybenzoyl) -3- (1-naphthyl) alanine, DL-N- (3-hydroxybenzoyl) -3- (1-naphthyl) alanine, DL- N- (4-hydroxybenzoyl) -3- (1-naphthyl) alanine, DL-N- (o-toluyl) -3- (1-naphthyl) alanine, DL-N- (m-toluyl) -3- ( 1-naphthyl) alanine, DL-N- (p-toluyl) -3- (1-naphthyl) alanine, DL-N- (1-naphthyl) -3- (1-naphthyl) alanine, DL-N- (2 -Naftoy ) -3- (1-naphthyl) alanine, DL-N- (2-carboxybenzoyl) -3- (1-naphthyl) alanine, DL-N- (3-carboxybenzoyl) -3- (1-naphthyl) alanine , DL-N- (4-carboxybenzoyl) -3- (1-naphthyl) alanine, DL-N- (2-picoline) -3- (1-naphthyl) alanine, DL-N- (3-picoline) 3- (1-Naphtyl) alanine, DL-N- (4-Picolyloyl) -3- (1-naphthyl) alanine, DL-N-phenylacetyl-3- (1-naphthyl) alanine, DL-N- (2 -Phenylpropanoyl) -3- (1-naphthyl) alanine, DL-N- (3-phenylbutyryl) -3- (1-naphthyl) alanine, DL-N- (4-methylvaleryl) -3- ( -Naphtyl) alanine, DL-N-valeryl-3- (1-naphthyl) alanine, DL-N- (4-methylvaleryl) -3- (1-naphthyl) alaninamide, DL-N- (4-methylvaleryl)- 3- (1-naphthyl) alanine methyl ester, DL-N- (4-methylvaleryl) -3- (1-naphthyl) alanine ethyl ester, DL-N- (4-methylvaleryl) -3- (1-naphthyl) alanine Propyl ester, DL-N- (4-methylvaleryl) -3- (1-naphthyl) alanine-N-butyl ester, DL-N- (4-methylvaleryl) -3- (1-naphthyl) alanine pentyl ester, DL- N- (4-methylvaleryl) -3- (1-naphthyl) alanine isopropyl ester, DL-N- (4-methylvaleryl) -3- ( 1-naphthyl) alanine isobutyl ester, and DL-N- (4-methylvaleryl) -3- (1-naphthyl) alanine-t-butyl ester), benzolactam derivatives, indolactam derivatives, cedrol, guaiool 1- (4- Hydroxyphenylthio) -2-propanol, β-lactoglobulin, 2-methoxy-5-methylphenol, 5-ethyl-2-methoxyphenol, 5-N-propyl-2-methoxyphenol, 5-N-butyl-2 -Methoxyphenol, 5-N-hexyl-2-methoxyphenol, 5-N-heptyl-2-methoxyphenol, 5-N-decyl-2-methoxyphenol, 5- (1,1-dimethylpropyl) -2- Methoxyphenol, 5- (1,1-dimethylbutyl) -2-methoxypheno 5- (1,1-dimethylethyl) -2-methoxyphenol, 2-methoxy-5- (1-methylpentyl) phenol, 2-methoxy-5- (1-methylhexyl) phenol, 2-methoxy-5 -(3-methylhexyl) phenol, 2-methoxy-5- (6-methylheptyl) phenol, 5- (1,3-dimethylheptyl) -2-methoxyphenol, murberine, feruginol, sugiol, cryptojaponol, 1 , 5-bis [p-hydroxyphenyl] -1,4-pentadien-3-one, 1,5-bis [o-hydroxyphenyl] -1,4-pentadien-3-one, 1,5-bis [2 , 4-Dihydroxyphenyl] -1,4-pentadien-3-one, 1,5-bis [3-methoxy-4-hydroxyphenyl] -1, 4-pentadien-3-one, haginin, agrimophor, agrimol, hydrangenol or derivatives thereof, alkylresorcinol or derivatives thereof (for example, 4-N-butylresorcinol), aristrone, caramenenes (for example, caramenene, 7- Hydroxycaramenene, 5-hydroxycaramenene and 7-methoxycaramenene), trans-umberic acid, N-alpha-benzoyl-L-arginine, N-alpha-benzoyl-L-arginine ethyl ester or N-alpha-benzoyl- L-arginine ethyl ester, 5-methyl-2 (3H) -furanone, 2-butene-4-olide, 2-hydroxymethylfuran, 2,5-dimethyl-4-hydroxy-3 (2H) -furanone, 2- Formyl franc, 3-formyl Lan, methyl alpha-furyl ketone, furfuryl acetate, 2-hydroxy-3-methyl-2-cyclopenten-1-one, 2-hydroxy-3,5-dimethyl-2-cyclopenten-1-one, 2,5-dimethyl -4-hydroxy-3 (2H) -thiophenone, 2-hydroxy-3-ethyl-2-cyclopenten-1-one, tetronic acid, pentanedione, iminodibenzyls (eg, 2,2′-iminodibenzyl, Imipramine, imipramine hydrochloride, desipramine, desipramine hydrochloride, chlorimipramine and trimipramine), dibenzocycloheptadienes (eg amitriptyline, amitriptyline hydrochloride, nortriptyline and noxiptylline), tetrahydrocopalol glycosides (eg ketochile fumarate) , Labda-8 (17), 13-dien-15-ol, tetrahydromanur, tetrahydrocoparol, tetrahydrocoparol glucoside, tetrahydrocoparol galactoside, tetrahydrocoparol maltoside, tetrahydrocoparol cellobioside, tetrahydro (Copalol maltotrioside), spiroether compound, piochelin, phenothiazine compound, promethazine, alimemazine, alimemazine tartrate, triflupromazine, levomepromazine, chlorpromazine, cyclandrate, 4-carboxymethyloxybenzoic acid, 4-carboxymethyloxy-2 -Hydroxybenzoic acid, 3- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 4- (3-carboxypropyl-1-oxy) benzoic acid 4- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 4- (3-carboxypropyl-1-oxy) -2-methoxybenzoic acid, 5- (3-carboxypropyl-1-oxy) ) -2-hydroxybenzoic acid, 4- (5-carboxypentyl-1-oxy) -2-hydroxybenzoic acid, 6- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 4- (10 -Carboxydecane-1-oxy) -2-hydroxybenzoic acid, 4- (10-carbamoyldecane-1-oxy) -2-hydroxybenzoic acid, 4- (4-hydroxybutyl-1-oxy) benzoic acid, 4 -(4-hydroxybutyl-1-oxy) -2-hydroxybenzoic acid, 4- (4-acetoxybutyl-1-oxy) benzoic acid, 4- (4-acetoxyb Til-1-oxy) -2-hydroxybenzoic acid, 4- (3-ethoxycarbonylpropyl-1-oxy) -2-hydroxybenzoic acid, 3- (2,3-dihydroxypropyl-1-o
Xyl) -2-hydroxybenzoic acid, 4- (4-methoxybutyl-1-oxy) -2-hydroxybenzoic acid, 4- (2,3-dihydroxypropyl-1-oxy) -2-hydroxybenzoic acid, 4 -Carboxymethyloxy-2-hydroxybenzoic acid, 3- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 4- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 5 -(3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 6- (3-carboxypropyl-1-oxy) -2-hydroxybenzoic acid, 4- (5-carboxypentyl-1-oxy)- 2-hydroxybenzoic acid, 4- (4-hydroxybutyl-1-oxy) -2-hydroxybenzoic acid, 4- (10-carboxydecane-1-oxy) ) -2-hydroxybenzoic acid, hydroxytrimethylcyclohexane (eg monosaccharide glycoside, disaccharide glycoside or trisaccharide glycoside, 2-hydroxy-4- (2,2,6-trimethyl-1-yl-cyclohexane) butane, 4 -(2,2,6-trimethyl-1-yl-cyclohexane) -1-butene, 4- (2,2,6-trimethyl-1-yl-cyclohexane) -2-butene, 4- (2,2, 6-trimethyl-1-yl-cyclohexane) butane, 3-methyl-3-hydroxy-5- (2,2,6-trimethyl-1-yl-cyclohexane) pentane, 3-methyl-1-hydroxy-5- ( 2,2,6-trimethyl-1-yl-cyclohexane) pentane, 3-methyl-5- (2,2,6-trimethyl-1-yl-cyclohexane) N-methyl, 3-methyl-1-hydroxy-5- (2,2,6-trimethyl-1-yl-cyclohexane) -3-pentene, 3-methyl-3-hydroxy-5- (2,2,6-trimethyl) -1-yl-cyclohexane) -1-pentene, 3-methyl-1-hydroxy-5- (2,2,6-trimethyl-1-yl-cyclohexane) -2-pentene, and 2-hydroxy-4- ( 2,2,6-trimethyl-1-yl-cyclohexane) butane), escinol, monosaccharide glycoside, parahydroxycinnamic acid-4- (2,2,6-trimethyl-yl-cyclohexane) -2-butyl ester Sugar glycoside, disaccharide glycoside or trisaccharide glycoside, ondisaponin, bacmond saponin, ruscogenin, sericoside, asiaticoside, hederin , Senegin, 4- (2,2,6-trimethyl-1-yl-cyclohexane) -2-keto-butane, 4- (2,2,6-trimethyl-1-yl-6-cyclohexene) -2-keto -Butane, 4- (2,2,6-trimethyl-1-yl-cyclohexane) -2-keto-3-butene, 4- (2,2,6-trimethyl-1-yl-6-cyclohexene) -2 -Keto-3-butene (β-ionone), Lp-hydroxyphenylglycine, Dp-hydroxyphenylglycine, N-benzyloxycarbonyl-Lp-hydroxyphenylglycine, N-benzyloxycarbonyl-D- p-hydroxyphenylglycine, N-benzoyl-Lp-hydroxyphenylglycine, N-benzoyl-Dp-hydroxyphenylglycine, N- (p- Toxibenzoyl) -Lp-hydroxyphenylglycine, N- (p-methoxybenzoyl) -Dp-hydroxyphenylglycine, N- (p-hydroxybenzoyl) -Lp-hydroxyphenylglycine, N- (p -Hydroxybenzoyl) -Dp-hydroxyphenylglycine, N-acetyl-Lp-hydroxyphenylglycine, N-acetyl-Dp-hydroxyphenylglycine, N-acetyl-Lp-hydroxyphenylglycine ethyl ester, N-acetyl-Dp-hydroxyphenylglycine ethyl ester, N-acetyl-Lp-hydroxyphenylglycinamide, N-acetyl-Dp-hydroxyphenylglycinamide, Lp-methoxyphenylglycine, D- p-Methoxyphenylglyci L-p-methoxyphenylglycine hydrochloride, Dp-methoxyphenylglycine hydrochloride, 4-hydroxy-3-methoxy-L-phenylglycine, 4-hydroxy-3-methoxy-D-phenylglycine, L- p-hydroxyphenylglycine ethylamide, Dp-hydroxyphenylglycine ethylamide, N-tert-butoxycarbonyl-Lp-hydroxyphenylglycine, N-tert-butoxycarbonyl-Dp-hydroxyphenylglycine, N- tert-butoxycarbonyl-Lp-methoxyphenylglycine, N-tert-butoxycarbonyl-Dp-methoxyphenylglycine, N-9-fluorenylmethyloxycarbonyl-Lp-methoxyphenylglycine, N-9 -Fluorenylmethylo Sicarbonyl-Dp-methoxyphenylglycine, N-9-fluorenylmethyloxycarbonyl-Lp-methoxyphenylglycine benzyl ester hydrochloride, N-9-fluorenylmethyloxycarbonyl-Dp-methoxy Phenylglycine benzyl ester hydrochloride, Lp-hydroxyphenylglycinamide, Dp-hydroxyphenylglycinamide, Lp-hydroxyphenylglycine allyl ester p-toluenesulfonate, Dp-hydroxyphenylglycine allyl ester p-toluenesulfonate, Lp-hydroxyphenylglycine benzyl ester p-toluenesulfonate, Dp-hydroxyphenylglycine benzyl ester p-toluenesulfonate, Lp-hydroxyphenylglycine Ethyl ester, Dp-hydroxyphenylglycine ethyl ester, Lp-hydroxyphenylglycine ethyl ester hydrochloride, Dp-hydroxyphenylglycine ethyl ester hydrochloride, Lp-hydroxyphenylglycine methyl ester and Dp -Hydroxyphenylglycine methyl ester, 1,3-diallylindane-2-carboxylic acid, stachybosine, pheophorbide derivative, eleucerin, isoeleucerine or 4-beta-hydroxyisoereucerine, eleucerinol, spiroketal derivative (for example, 2- (2 , 4-Hexadiynylidene) -1,6-dioxaspiro [4.5] dec-3-ene, 2- (2-hexynylidene) -1,6-dioxaspiro [4.4] non-3-ene, 2- ((4-Methylphenol Enyl) methylidene) -6,6-dioxaspiro [4.4] non-3-ene, 2- (2-hexenylidene) -6,6-dioxaspiro [4.5] dec-3-ene, 2- (2- Hexenylidene) -1,6-dioxaspiro [4.4] non-3-ene, 2-hexyl-1,6-dioxaspiro [4.4] nonane, 2- (2-hexenyl) -1,6-dioxaspiro [4 .4] nonane, 2- (2-hexynyl) -1,6-dioxaspiro [4.4] nonane, 2-pentyl-1,6-dioxaspiro [4,4] nonane, 1,6-dioxaspiro [4.4 Nonane, 1,6-dioxaspiro [4.5] decane, 1,7-dioxaspiro [5.5] undecane, 2,3-benzo-4,4-dimethyl-1,6-dioxaspiro [4.4] nonane 3,4-be Zo-2-pentyl-1,6-dioxaspiro [4.4] nonane, 3,4-benzo-2-hexyl-1,6-dioxaspiro [4.4] nonane, 3,4-benzo-2-octyl- 1,6-dioxaspiro [4.4] nonane, 2-hexyl-9,9-dimethyl-1,6-dioxaspiro [4.4] nonane, and 2- (2,4-hexadinylidene) -1,6 -Dioxaspiro [4.4) non-3-ene), malvalic acid, phosphonic acid derivatives or their salts, aspergillomarasmine, aminophosphonic acid derivatives or their salts, diphenhydramine or their salts, pregnenolone or their derivatives , Lutein, farnesyl isopropanol derivative, hexahydrofarnesyl acetone, 4-benzoylamino-2-hydroxyl Perfume acid, 5-benzoylamino-2-hydroxybenzoic acid, 4-benzoylaminobenzoic acid, 4- (1-naphthoylamino) -2-hydroxybenzoic acid, 5- (1-naphthoylamino) -2-hydroxy Benzoic acid, 4- (2-naphthoylamino) -2-hydroxybenzoic acid, 5- (2-naphthoylamino) -2-hydroxybenzoic acid, 4- (1-naphthoylamino) benzoic acid, 4- ( 2-naphthoylamino) benzoic acid, 4-phenylaminocarbonylbenzoic acid, 4-phenylaminocarbonyl-2-hydroxybenzoic acid, 5-phenylaminocarbonyl-2-hydroxybenzoic acid, 4- (1-naphthylaminocarbonyl) Benzoic acid, 4- (1-naphthylaminocarbonyl) -2-hydroxybenzoic acid, 5- (1-naphthylaminocarbonyl)- 2-hydroxybenzoic acid, 4- (2-naphthylaminocarbonyl) benzoic acid, 4- (2-naphthylaminocarbonyl) -2-hydroxybenzoic acid, 5- (2-naphthylaminocarbonyl) -2-hydroxybenzoic acid, Hexahydrofarnesyl isopropanol derivative, borneol-p-hydroxycinnamic acid glucoside, borneol-p-hydroxycinnamic acid maltoside, borneol-p-hydroxycinnamic acid maltotrioside, cinnamic acid-4- (2, 2,6-trimethyl-yl-cyclohexane) -2-butyl ester derivative, 2,4-dihydroxybenzophenone, 1- (2,4-dihydroxyphenyl) -ethanone (2 ′, 4′-dihydroxyacetophenone), 1- ( 2,4-dihydroxyphenyl)- -Propanone (21,4'-dihydroxypropiophenone), 1- (2,4-dihydroxyphenyl) -1-butanone, 1- (2,4-dihydroxyphenyl) -1-pentanone, 1- (2,4 -Dihydroxyphenyl) -1-hexanone, 1- (2,4-dihydroxyphenyl) -1-heptanone, 1- (2,4-dihydroxyphenyl) -1-octanone, 1- (2,4-dihydroxyphenyl)- 1-nonanone, 1- (2,4-dihydroxyphenyl) -1-decanone, 1- (2,4-dihydroxyphenyl) -1-undecanone, 1- (2,4-dihydroxyphenyl) -1-dodecanone, -(2,4-dihydroxyphenyl) -1-tetradecanone, 1- (2,4-dihydroxyphenyl) -1-hexadecanone, 1- (2, -Dihydroxyphenyl) -1-octadecanone, 1- (2-hydroxy-4-methoxyphenyl) -ethanone (2'-hydroxy-4'-methoxyacetophenone), 1- (2-hydroxy-4-methoxyphenyl) -1 -Propanone (2'-hydroxy-4'-methoxypropiophenone), 1- (2-hydroxy-4-methoxyphenyl) -1-butanone, 1- (2-hydroxy-4-methoxyphenyl) -1-pentanone 1- (2-hydroxy-4-methoxyphenyl) -1-hexanone, 1- (2-hydroxy-4-methoxyphenyl) -1-heptanone, 1- (2-hydroxy-4-methoxyphenyl) -1- Octanone, 1- (2-hydroxy-4-methoxyphenyl) -1-nonanone, 1- (2-hydroxy-4-methoxyphenyl) Nyl) -1-decanone, 1- (2-hydroxy-4-methoxyphenyl) -1-undecanone, 1- (2-hydroxy-4-methoxyphenyl) -1-dodecanone, 1- (2-hydroxy-4- Methoxyphenyl) -1-tetradecanone, 1- (2-hydroxy-4-methoxyphenyl) -1-hexadecanone, 1- (2-hydroxy-4-methoxyphenyl) -1-octadecanone, 1- (4-hydroxy-2) -Methoxyphenyl) -ethanone (4'-hydroxy-2'-methoxyacetophenone), 1- (4-hydroxy-2-methoxyphenyl) -1-propanone (4'-hydroxy-2'-methoxypropiophenone), 1- (2,4-Dimethoxyphenyl) -ethanone (2 ′, 4′-dimethoxyacetophenone 1- (2,4-dimethoxyphenyl) Enyl) -1-propanone (2 ′, 4′-dimethoxypropiophenone), lactone derivatives (eg, 1,6-dioxaspiro [4.4] nonane-2,7-dione, 1,6-dioxaspiro [4. 5] Decane-2,7-dione, 4-tridecanolide,
4-dodecanolide, 4-undecanolide, 4-decanolide, 4-nonanolide, 4-octanolide, 4-heptanolide, 5-dodecanolide, 5-undecanolide, 5-decanolide, 5-nonanolide, 5-octanolide, 2-undecen-4- Orido, 2-Decene-4-Olide, 2-Nonene-4-Olide, 2-Heptene-4-Olide, 2-Undecen-5-Olide, 2-Decene-5-Olide, 2-Nonene-5-Olide, 2-octene-5-olide, 4-methyl-4-dodecanolide, 4-methyl-4-undecanolide, 4-methyl-4-decanolide, 4-methyl-4-nonanolide, 4-methyl-4-heptanolide, 5- Methyl-5-dodecanolide, 5-methyl-5-undecanolide, 5-methyl-5-decanolide, 5-methyl-5-nonanolide, 5 Methyl-5-octanolide, 2-methoxycarbonyl-4-dodecanolide, 2-methoxycarbonyl-4-undecanolide, 2-methoxycarbonyl-4-decanolide, 2-methoxycarbonyl-4-nonanolide, 2-methoxycarbonyl-4-heptanolide 2-methoxycarbonyl-5-undecanolide, 2-methoxycarbonyl-5-decanolide, 2-methoxycarbonyl-5-nonanolide, 2-methoxycarbonyl-5-octanolide, 2-allyl-4-undecanolide, 2-allyl-5 -Decanolide, 2-allyl-4-nonanolide, 2-pentyl-4-undecanolide, 2-pentyl-4-nonanolide, 2-methyl-4-undecanolide, 2-methyl-4-nonanolide, 2- (4-hydroxybutyl) ) -4-Undecanolide, 2 (4-hydroxybutyl) -4-nonanolide, 2- (4-hydroxybutyl) -5-decanolide, 5-propyloxy-4-pentanolide, 5-allyloxy-4-pentanolide, 5- (2-hydroxyethoxy)- 4-pentanolide, 8-hydroxy-4-octanolide, 6-propyloxy-5-hexanolide, 6-allyloxy-5-hexanolide, 6- (2-hydroxyethoxy) -5-hexanolide, and 9-hydroxy-5-nonanolide ), Ethinomycin, iriflorental, iriparidal, 2'-8-C-glucosyl-7-methyl aloesol coumaroyl ester, 2'-8-C-glucosyl-7-methyl aloesol cinnamoyl ester, chloropyramine, anise Extract, Aloe extract, Japanese knotweed (HU ZHANG ) Extract, Naniwazu extract, Shrimp extract, JUE MING ZI (Ebiscus seed, Cassiae Semen) extract, HUANG QI (Astragali radix) extract, Astragali radix extract, Dwarf root Extract, CHANG ER ZI extract, TIAN MA extract, oyster extract, giant redbird extract, WU YAO (Linderae Radix) extract, pumpkin extract, PU HUANG Extract, GAN SUI extract, XIAN HE CAO extract, black moji extract, black spruce extract, agave sisalana extract, saximar button krill extract, sina Tan extract, WEI RING XIAN extract, Oshima cherry extract, Oyama cherry extract, bean cherry extract, Takane cherry extract, Kohigan extract, Sato cherry extract, Zion (ZI WAM) extract, palm extract , White squirrels extract, EA LIAO extract, extract of XIN YI HUA, dimonds extract, camellia extract, TU SI ZI (root beetle root) extract, bean extract, beetle extract, Butterberry extract, Yarrow extract, Baku Xian PI extract, Dill extract, Honey beetle extract, Crane extract, SHI WEI extract, Cicada (XIAN PU) extract, Bikushi extract , Floral Nuka extract, hamula extract, sagebrush extract, convolvulaceae extract, sandalwood extract, lingu shii extract (LING SHI) extract, oyster mushroom (YI MU CAO) extract, kawayanagi extract, akame willow extract, cat willow extract, Incolyana extract, Kinuyanagi extract, Koryanagi extract, Unryu willow extract, Miyama willow extract, Willow willow extract, Oba willow extract, Tairikinu willow extract, Fox willow extract, Doronoki extract, Yamamomo (YANG MEI PI) , Agave extract, aolan agave extract, agave extract, mitsumata extract, aonori (green layer) extract, usba aonori extract, sugiaonori extract, hiraaoonori extract, bouaoonori extract, hosoeda Onori extract, Kombu (comb) extract, Macombu extract, Rishikonbu extract, Hosome Kombu extract, Mitsuishi Kombu extract, Wakame extract, Hirome extract, Aowakame extract, Hijiki extract, Hibamata extract, Umiuchiwa extract , Usubau miuchiwa extract, Kirebano miuchiwa extract, Akaba miuchichiwa extract, Kona miuchiwa extract, Okinawa chiwa extract, Usukiuchichiwa extract, Etsumi michiwa extract, Togekirinsai extract, Amakusarinsai extract, Giraffe rhinoceros extract Juniper ginseng extract, Tsunomata extract, Ibottsumata extract, Marubatsunomata extract, Hiratokoji extract, Sugi nori extract, Shikinori extract, Kainori extract, Yakuzusa extract, Urabo shiyahaz extract, Umiuchiwa extract, Ishimozuku extract , Misjikonbu extract, Atsumi mischimbu extract, Isomoku extract, Nagashima Moku extract, Shidamoku extract, Nejimoku extract, Narasamo extract, Mametawara extract, Tatsukuri extract, Yatsumata moku extract, Umitorano extract, Oobamoku extract , Fusiform moku extract, haha moku extract, yoremoku extract, sawtooth moku extract, plantain mokumoku extract, mukadenori extract, nuraksa extract, cronouraxa extract, omkadenori extract, matsunori extract, giant scorpion extract, silkworm extract , Fushitsunagi extract, Himefutsutsugi extract, Hirohafutsutsugi extract, Kurosozo extract, Kobosozo extract, Hanesozo extract, Sozonohana extract, Hazelwood sawtooth extract, Thira extract, Camote de azafuran extract, Hamica extract Examples include extracts, Poleo verde extract, lavender extract, datura extract, pine beetle extract and sage extract.

Optical brightener The topical cosmetic composition may optionally further comprise one or more optical brighteners. The fluorescent whitening agent is described in Fluorescent Whiting Agent, Encyclopedia of Chemical Technology, Kirk-Othmer, Vol. 11, pages 227-241, 4th edition, 1994, Wiley, which is incorporated herein by reference in its entirety. Has been. Optical brighteners can be defined in more detail as compounds that absorb between 300 nm and 390 nm in the UVA range and essentially re-emit between 400 nm and 525 nm. Suitable optical brighteners include, but are not limited to, stilbene derivatives (eg, 4,4′-bis [(4,6-dianilino-1,3,5-triazin-2-yl) amino] stilbene- 2,2′-disulfonate), coumarin derivatives, oxazole and benzoxazole derivatives (eg, 2,5-thiophenezylbis (5-tert-butyl-1,3-benzoxazole)) and imidazole derivatives Or may consist of them. The amount of optical brightener is generally in the range of about 0.1% to about 5.0% based on the total weight of the composition. A suitable optical brightener is oxazole.

Anti-inflammatory agent The topical cosmetic composition may optionally further comprise one or more anti-inflammatory agents. Suitable anti-inflammatory agents useful in this regard include, but are not limited to, propionic acid derivatives, acetic acid derivatives, phenamic acid derivatives, biphenyl carboxylic acid derivatives, oxicam, acetylsalicylic acid, ibuprofen, naproxen, beoxaprofen, flurule. Biprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pyrprofen, carprofen, oxaprozin, pranoprofen, microprofen, thixaprofen, suprofen, aluminoprofen, thiaprofenic acid, fluprofen, bukuroku Chic acid, apazone, bromfenac, celecoxib, diclofenac, difenpyramide, diflunisal, etodolac, flufenamic acid, indomethacin, ketorolac, meclofena , Mefenamic acid, meloxicam, nabumetone, phenylbutazone, piroxicam, butibufen, rofecoxib, salicylic acid, sulindac, tolmetine, ketorolac tromethamine, antihistamine, diphenhydramine, chlorpheniramine, diphenhydramine hydrochloride, chlorpheniramine corolate maleate Costeroid, alclomethasone, dexamethasone, flumethasone, hydrocortisone, hydrocortisone-21-monoester, hydrocortisone-21-acetate, hydrocortisone-21-butyrate, hydrocortisone-21-propionate, hydrocortisone-21-valerate, hydrocortisone-17,21-diester, Hydrocortisone-17,21-diacetate, hydrocortisone-17- Cetate-21-butyrate, hydrocortisone-17,21-dibutyrate, prednisolone, methylprednisolone, betamethasone benzoate, betamethasone dipropionate, clobetasol propionate, difluorazone diacetate, fluocinonide, fluticasone propionate, mometasone acetonidone propionate , Topical corticosteroids, hydroxytriamcinolone, alpha-methyldexamethasone, dexamethasone phosphate, clobetasol valerate, desonide, desoxymethazone, desoxycorticosterone acetate, dexamethasone, dichlorizone, diflorazone diacetate, diflucortron valerate, fluadrenolone , Fluchlorolone acetonide, fludrocortisone, flumethasone pivalate, fluo Cinolone acetonide, fluocinonide, flucortin butyl ester, fluocortron, fluprednidene acetate (fluprednidene), flulandenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, Medrizone, Amsiafel, Amsinafide, Betamethasone, Chloroprednisone, Chloroprednisone acetate, Crocorterone, Cresinolone, Dichlorizone, Diflupredone, Fluchloronide, Flunizolide, Fluorometasone, Flupelone, Fluprednisolone, Hydrocortisone valerate, Hydrocortisone cyclopentylpropionate Mate, Meprednisone, Parameter Zon, Donison, beclomethasone dipropionate, triamcinolone, isoxicam, tenoxicam, sudoxicam, CP-14, 304, salicylate, disalside, benolylate, trilysate, saphapurine, sorprine, fendosaur, fenclofenac, indomethacin, sulindac, tolmethine, isoxepac, , Thiopinac, zidomethacin, acetamacin, fenthiazac, zomepirac, clindanac, oxepinac, felbinac, ketorolac, fenamic acid, mefenamic acid, meclofenamic, meclofenamic, flufenamic, niflumic, tolfenamic acid, pyrazole, phenylbutazone, oxybutazone Azaprapazone, trimethasone, candelilla wax, bisabolol, Includes Rufavisabolol, True Aloe, Plant Sterol, Phytosterol, Manjistha, Guggal, Cola Extract, Chamomile, Purple Duckweed Extract, Hippopotamus Extract, Ganoderma Extract, Mustard Goat Extract and Mixtures thereof .

Antibacterial agents Non-limiting examples of suitable antibacterial and antifungal agents useful in this regard include, but are not limited to, beta-lactams, quinolones, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin 2,4,4′-trichloro-2′-hydroxydiphenyl ether, 3,4,4′-trichlorovanylide, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clinda Mycin, ethambutol, hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, linomycin, metacycline, mesenamine, minocycline, neo Mycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole, tetracycline hydrochloride, zinc erythromycin, erythromycin estrate, erythromycin stearate, amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, chlortetracycline hydrochloride , Clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineneomycin hydrochloride, metacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmycin sulfate, paromomycin sulfate, sulfuric acid Streptomycin, sulfuric acid Bramycin, miconazole hydrochloride, amanfazine hydrochloride, amanfazine sulfate, octopirox, parachlorometaxylenol, nystatin, tolnaftate, clotrimazole, benzoyl peroxide, azelaic acid, ethyl acetate, meclocycline, lincomycin, tetracycline, sulfur Based antibiotics, sulfonamides, mupirocin, magainin I, magainin II, lincomycin, (6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl) -carbonyl] amino] -1-thio-L-threo-alpha-D-galacto-octopyranoside), 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl) carbonyl]- Amino] -1-thio-L- Leo-alpha-D-galacto-octopyranoside, (4- (dimethylamino) -1,4,4-alpha, 5,5-alpha, 6,11,12-alpha-octahydro-3,6,12,12- Alpha-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide), chlortetracycline, demeclocycline, lolitetracycline, sulfacetamide, sulfabenzamide, sulfadiazine, sulfadoxine, sulfamerazine, sulfamethazine, Sulfamethizole, sulfamethoxazole, sulfacetamide sodium, amphotericin B, benzoic acid, butenafine, butenafine HCl, butconazole, butconazole nitrate, caprylic acid, chloroxylenol, cyclopyrox, Clotrimazole, econazole, econazole nitrate, fuconazole, itraconazole, ketoconazole, miconazole, miconazole nitrate, naphthifine, naphthifine hydrochloride, nystatin, oxyconazole, oxyconazole nitrate, salicylic acid, selenium, selenium sulfide, sulconazole, sulconazole nitrate, terbinafine, Terbinafine hydrochloride, terconazole, thioconazole, undecylenic acid, acitretin, alcromethasone dipropionate, anthralin, azathioprine, calcipotriene, calcitriol, colchicine, cyclosporine, methoxalene, retinoid, 3-hydroxybenzoic acid, glycolic acid, lactic acid, 4-hydroxy Benzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydride Xylpentanoic acid, 2-hydroxyhexanoic acid, azelaic acid, arachidonic acid, benzethonium chloride, benzalkonium chloride, boric acid, 8-quinolinol benzoate, secondary amyltricresole, cetylpyridinium chloride, chlorothymol and 8-hydroxyquinoline sulfate, Including their pharmaceutically or cosmetically acceptable salts and mixtures thereof.

Anti-wrinkle and anti-atrophy agents The topical cosmetic composition may optionally further comprise one or more anti-wrinkle agents and / or anti-atrophy agents. Suitable non-limiting examples of anti-wrinkle and / or anti-atrophy agents useful in this regard include one or more cis and trans retinoic acids, retinol, retinyl esters, salicylic acid, sulfur containing D and L amino acids, N-acetyl derivatives, sulfur-containing D and L amino acids, N-acetyl-L-cysteine, thiols, ethanethiol, alpha-hydroxy acid, glycolic acid, lactic acid, phytic acid, lipoic acid, lysophosphatidic acid, skin exfoliant, It may contain anti-wrinkle agents and / or anti-atrophy agents that may comprise or consist of phenol, their pharmaceutically and cosmetically acceptable salts and mixtures thereof.

Anti-Acne Agents The topical cosmetic composition can optionally further comprise one or more anti-acne agents. Suitable non-limiting examples of anti-acne agents useful in this regard include one or more keratolytic agents, salicylic acid (o-hydroxybenzoic acid), 5-octanoyl salicylic acid, resorcinol, retinoids, cis and trans retinoin. Acid, sulfur-containing D and L amino acids, N-acetyl sulfur-containing D and L amino acids, N-acetyl-L-cysteine, lipoic acid, sevostarte, flavonoids, bile acids, simnol sulfate, deoxycholic acid, cholic acid, adapalene , Azelaic acid, benzoyl peroxide, clindamycin, clindamycin phosphate, doxycycline, erythromycin, norgestimate, organic peroxide, isotretinoin, tretinoin, sodium sulfacetamide, tazarotene, and their pharmaceutical and cosmetic products Or including acceptable salts and mixtures thereof Te, or may include an anti-acne agent which may be composed of them.

Treatment method
In one embodiment, the present invention relates to a method of treating a subject's skin comprising topically administering to the skin of a subject in need thereof a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein. .

  In one embodiment, the present invention whitens skin pigmentation in a subject comprising topically administering to the skin of the subject in need thereof a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein. Regarding the method.

  In another embodiment, the present invention provides a skin disorder or condition of a subject comprising topically administering to the skin of a subject in need thereof a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein. It relates to the treatment method. The skin disorder or condition can be a disorder or condition associated with undesirable skin pigmentation.

  In another embodiment, the present invention provides a therapeutically effective amount of a topical cosmetic composition according to the present invention as described herein at least once per day for at least 3 days, at least 5 days, to the skin of a subject in need thereof. Or a method of whitening skin pigmentation in a subject or treating a skin disorder or condition in a subject comprising topical administration for at least 7 days. In this regard, the skin after 3 days, 5 days, or 7 days after administration of the topical composition of the present invention to the skin is visibly changed.

  In one embodiment, the invention comprises topically administering a therapeutically effective amount of a topical cosmetic composition according to the invention as described herein to the skin of a subject in need thereof at least once per day for at least 3 weeks. The present invention relates to a method of whitening skin pigmentation of a subject or a method of treating a skin disorder or condition of a subject, wherein the skin is visibly whitened after 3 weeks.

  The topical cosmetic compositions of the present invention are effective in treating various skin disorders or conditions characterized by undesirable skin pigmentation. Non-limiting examples of such disorders and / or conditions include parts caused by hyperfunctioning melanocytes such as idiopathic melasma (gestational melasma or brown spots) occurring during pregnancy or after estrogen-progesterone contraception Hyperpigmentation, local hyperpigmentation caused by benign melanocyte hyperfunction and proliferation such as senile mole known as melasma, accidental hyperpigmentation such as photosensitization and scarring after injury, freckles Certain forms, such as vitiligo, whitening or depigmenting the remaining areas of normal skin to give a uniform color throughout the skin, when pigmentation disorders, and damaged skin cannot be recolored May include vitiligo. The skin is not desired for pigmentation, but can be treated by the methods described herein for pure cosmetic whitening of areas of the skin that are suitable for the individual's skin type, eg, large areas. In one embodiment, the skin disorder or condition treated by the methods of the present invention is undesirable skin pigmentation. Administration of the topical cosmetic compositions of the present invention to areas of skin containing undesirable pigmentation will whiten those areas. Thus, the method of the present invention whitens the area of skin to which the topical cosmetic composition of the present invention has been administered.

  Skin areas suitable for treatment and / or whitening according to the invention described herein may include, for example, thin skin areas, including areas of the face, neck and / or hand skin. The compositions and methods of the present invention described herein are suitable for use in both men and women and are suitable for use on all skin types, including dry skin types, normal skin types, and oily skin types.

  In embodiments, the present invention provides a method of treating a skin disorder or condition in a subject, or a method of whitening skin pigmentation in a subject, wherein topical administration to the skin is at least once per day or at least twice per day, at least It relates to a method in which skin pigmentation is whitened, comprising administering for 2 weeks. Topical administration can include administering at least once per day or at least twice per day for at least 3 weeks, and skin pigmentation is whitened. Topical administration can include administering at least once per day or at least twice per day for at least 4 weeks, and skin pigmentation is whitened. Administering at least once per day includes administration once in the morning or evening. Administering at least twice per day includes administration once in the morning and evening.

Methods of Manufacture Various formulations of the inventive topical cosmetic composition according to the present invention described herein include such formulations, including, for example, creams, gels, serums, lotions or other formulations described herein. It can be easily manufactured by a person skilled in the art without undue experimentation by a known method of manufacturing.

  The manufacturing process of the cream or emulsion formulation may involve preparing the aqueous phase and the oil phase separately, for example adding the oil phase to the aqueous phase while mixing and / or homogenizing (at high shear) to make an emulsion. . After the emulsion is formed, the following ingredients, one or more pH adjusters, one or more emollients, one or more skin lightening actives, one or more sunscreen actives, One or more of one or more thickeners, one or more antioxidants and one or more perfumes are optionally added to them in the following order, for example, to give the final emulsion or cream Can be manufactured. Prior to forming the emulsion, the aqueous and oil phases may be separately heated to a temperature of about 70 ° C to about 99 ° C, about 75 ° C to about 95 ° C, about 80 ° C to about 90 ° C, or about 85 ° C. After heating, the oil phase can be slowly added to the aqueous phase, for example with mixing or high shear homogenization. The resulting emulsion is then maintained at, for example, about 47 ° C to about 27 ° C, about 42 ° C to about 30 ° C, about 39 ° C to about 35 ° C, or about 37 ° C while maintaining mixing and high shear homogenization. Can be cooled to temperature. Thereafter, one or more of the optional ingredients described above can then be added to the cooled emulsion, for example, with mixing and / or high shear homogenization. The resulting emulsion or cream may have a pH of about 4.5 to about 6.5 and / or a viscosity of about 5000 cP to about 15000 cP and / or a density of about 1.01 to about 1.06. .

  Furthermore, the scope of the present invention contemplates topical cosmetic compositions made according to the foregoing process. If produced by these processes, these compositions exhibit chemical and physical stability suitable for topical administration.

  The topical cosmetic composition produced by these processes is a product contact surface comprising a material selected from the group consisting of glass, plastic, steel, stainless steel, aluminum, Teflon, polymer structure, ceramic structure, alloy and mixtures thereof. Can be placed in a suitable closed container containing These sealed containers are used to facilitate the manufacture, handling, processing, packaging, storage and administration of the topical cosmetic composition. Suitable sealed containers in this regard may be selected from the group consisting of plastic tubes, bottles, metal tubes and any combination thereof.

Route of Administration / Dosage To be effective, the route of administration of the topical cosmetic composition used in the method of the present invention must readily affect the target skin area. In most cases, effective results are achieved by applying a thin layer locally to the affected area or areas where it is desired to achieve the desired effect. Effective results can be achieved with application rates from once applied every two or three days to four or more times per day.

  Appropriate dosage levels of active agents contemplated in the topical cosmetic compositions and methods of the present invention are well known to those skilled in the art and are selected to maximize the treatment of the aforementioned skin conditions. Dosage levels on the scale of about 0.001 mg to about 5000 mg of skin lightening active ingredient per kilogram body weight are known to be useful in the treatment of the diseases, disorders and conditions contemplated herein. Generally, this effective amount of skin lightening active ingredient generally comprises from about 0.001 mg to about 100 mg per kilogram of patient body weight per day. In addition, it is to be understood that this dosage component can be administered in one or more dosage units to provide the desired therapeutic effect.

  If desired, other therapeutic agents can be used in combination with those listed above for the composition. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder or condition and the nature of the active ingredient.

  The compositions of the invention can be administered daily in single or multiple doses. In one embodiment, the topical cosmetic composition of the present invention is administered 1 to 4 times daily. If necessary, one plan is to start once or twice daily at low doses and slowly increase to higher doses. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host treated, the nature of the disease, disorder or condition and the nature of the active ingredient. In one embodiment, the topical cosmetic composition can be topically applied one or more times per day. In one embodiment, the topical cosmetic composition of the present invention is topically applied 1 to 4 times daily. For example, one plan is to start once daily and increase to more frequent application if necessary.

  In one embodiment, the topical cosmetic composition of the present invention is topically applied 1 to 4 times daily, for example, in the morning, noon, afternoon, and / or night. For example, the topical composition can be applied topically once a day in the morning, noon, afternoon or night. The topical composition can be applied topically twice a day, for example, morning and night, noon and night, morning and noon, morning and afternoon, afternoon and night. This topical composition can be topically applied three times a day, for example, in the morning, noon or afternoon, and at night. This topical composition can be topically applied four times a day, for example, in the morning, noon, afternoon, and night.

  In one embodiment, the topical cosmetic compositions described herein can be administered one or more times per day, at least 1 week, at least 2 weeks, at least 4 weeks, or at least 8 weeks. The topical cosmetic composition can be administered one or more times per day, up to 1 year, up to 6 months, up to 3 months or up to 2 months. The topical cosmetic composition may be one or more times per day, at least 1 week to 1 year, at least 1 week to 6 months, at least 1 week to 4 months, at least 1 week to 3 months, at least 1 week to 2 months For at least 2 weeks to 2 months, at least 3 weeks to 2 months, at least 1 week to 1 month, at least 1 week to 3 weeks, or at least 4 weeks to 2 months.

  However, the specific dose level for any specific patient is the activity of the specific active agent, the patient's age, weight, general health, sex and diet, administration time, excretion rate, possible concomitant medications It will be appreciated that it will vary depending on a variety of factors, including the severity of the particular condition being treated and the mode of administration. One skilled in the art will understand the variety of such factors and will be able to establish a particular dose level using only routine experimentation.

  Pharmacological parameters such as bioavailability, absorption rate constant, apparent distribution, unbound fraction, total clearance, fraction excreted unchanged, first-pass metabolism, elimination rate constant, halved The period and average residence time are well known in the art.

  The optimal cosmetic formulation can be determined by one skilled in the art depending on considerations such as the particular ingredients and the desired dosage. For example, Remington's Pharmaceutical Sciences, 18th edition (1990, Mack Publishing Co., Easton, PA 18042) 1435-1712 and “Harry's Cosmeticology, the entire disclosures of which are hereby incorporated by reference. ", 8th edition (2000, Chemical Publishing Co., Inc., New York, NY 10016). Such formulations can affect the general condition, stability, release rate in vivo and clearance rate in vivo.

  In one embodiment, the topical cosmetic composition of the invention according to the invention described herein is for example a gel cream encapsulated in a tube or a serum encapsulated in a non-aerosol non-foaming pump container or bottle, for example. The amount of the composition contained in the container can be in the range of about 10 gm to about 60 gm, between about 20 gm and about 50 gm, or about 30 gm, or about 40 gm.

  Single dose kits and packages containing a single dose of composition per day can be prepared. Single doses, unit doses and once daily disposable containers of the compositions of the invention are contemplated as within the scope of the invention.

  The topical cosmetic compositions of the invention according to the invention described herein can be formulated for storage in a substantially non-reactive laminated package in order to increase the stability of the package. This storage method exhibits enhanced packaging stability compared to other paper-based packaging.

  The amount of composition per single package can be between about 0.1 ml to about 20.0 ml, between about 0.5 ml and about 5.0 ml, or between about 1 ml and about 3 ml.

  In particular, the ability to formulate compositions that can be pre-mixed prior to application or stored for long periods without the need for compounding is also contemplated. Specifically, the compositions of the present invention can be between about 3 months and about 3 years, between about 3 months and about 2.5 years, between about 3 months and about 2 years, about 3 months and about 20 months. Maintains unexpected stability during storage for a period of between, or any period between about 6 and about 18 months.

  In one embodiment, the topical cosmetic formulations described herein according to the invention described herein remain stable for at least 3 years at a temperature of less than 30 ° C. In one embodiment, the topical cosmetic formulations described herein remain stable for at least 2 years at a temperature of 30 ° C. or lower. In one embodiment, the topical cosmetic formulations described herein remain stable for at least 2 years at a temperature of 25 ° C. or lower.

  The following examples illustrate the topical cosmetic compositions of the present invention and are not meant to be limiting thereto. Any polymer molecular weight is an average of the average molecular weight. Unless otherwise noted, all percentages are based on the weight percent of the final delivery system or prepared formulation, and the total is all equal to 100% by weight.

Example 1
The following examples illustrate the apparent effectiveness of the topical cosmetic compositions of the present invention compared to a 2% hydroquinone composition as measured by the colorimetric instrument method.

  In a single-center, double-blind, comparative clinical trial over a 6 week period, the apparent effectiveness of each of the two topical products was evaluated on the already pigmented skin of 10 volunteers. Dermatological evaluation was performed at the start and end of the study. Skin color was measured by a colorimeter with photographic records at T0, T07, T14 and T21. UVB pigmentation was induced in the volunteer's already pigmented skin using a solar simulator equipped with a light source, ie, a xenon arc lamp 601 / 300W manufactured by Solar Light CO.

Skin coloration was measured using a Minolta color difference meter CR400 (The Commission International de I'Eclairage) with standard color system CIE. The color is expressed by a three-dimensional coordinate system in which the L ^* axis corresponds to skin lightness, the a ^* axis corresponds to green and red, and the b ^* axis corresponds to blue and yellow.

  A solar simulator equipped with a xenon arc lamp 601 / 300W manufactured by Solar Light CO was used as the light source. This device provides continuous light emission in the UVB and UVA spectra in the range of 290 and 400 nm. The device includes a series of lenses and a filter that absorbs or disperses radiation below 320 nm or above 400 nm. Irradiation is performed from six branched optical fibers called “ports” that are set to apply pre-established individual doses. Irradiation monitoring was performed using a dose control system (DCS) including a UVB irradiation detector and an electronic monitor. In this test, only three “ports” were used at each application site of the test composition.

Evaluation sample

Formulation production method Disperse methylene bis-benzotriazolyl tetramethylphenol in a small amount of purified water in a suitable container. Mix until uniform.
2. In a suitable container, blend until the cyclopentasiloxane PEG / PPG-18 / 18 dimethicone and cyclopentasiloxane dimethicone crosspolymer are uniform.
3. Place polyethylene glycol in a suitable container. Add licorice extract and disperse. Mix until uniform.
4). Disperse the fruit extract of Filanthus embrica in a small amount of purified water in a suitable container. Mix until uniform.
5. Disperse triethanolamine in a small amount of purified water in a suitable container. Mix until uniform.
6). Disperse sodium metabisulfite in a small amount of purified water in a suitable container. Mix until uniform.
7). Add the remaining purified water while mixing to the main production vessel and disperse the sodium edetate. Heat the contents to about 85 ° C.
8). To a suitable container, add cetyl alcohol, C _14-22 alcohol and C _12-20 alkyl glycoside, cetyl alcohol, ethylhexyl methoxycinnamate and butylated hydroxytoluene. Heat to about 85 ° C. and mix until uniform.
9. Add the Step 8 mixture to the Step 7 mixture with stirring. Mix until uniform.
10. Cool the batch to about 37 ° C. while mixing.
11. Add the mixture of step 4 and step 5 while mixing. Mix until uniform.
12 Add phenoxyethanol and methylisothiazolinone with mixing.
13. While mixing, add the mixture of step 2 and then the mixture of step 3. Mix until uniform.
14 Add Belis Perennis flower extract and mix until uniform.
15. While mixing, add the mixture from step 1 and mix until uniform.
16. Add hydroxyethyl acrylate, sodium acryloyldimethyltaurate copolymer, squalene and polysorbate 60. Mix until uniform.
17. Add the mixture from step 6 while mixing. Mix until uniform.
18. Add perfume while mixing. Mix until uniform.

Screening for volunteers Collective sampling:
Ten volunteers aged 18 to 60 were screened for study implementation. Participating subjects were given the first four letters of the name and the first letter of the last name, an individual identification number (created by the electronic system) and a protocol number.

2. Selection criteria Age level: 18 to 60 years old Phototype II and III according to Fitzpatrick classification
-Whole skin of the test site-Consent to visit the clinic on the date and time specified for evaluation according to the test method-Signature of informed consent form

3. Exclusion criteria • Pregnancy or breastfeeding • Use of anti-inflammatory or immunosuppressive agents • Personal history of atopy • Use of local or systemic photosensitization therapy • History of phototoxic or photoallergic reactions • Sensitization or irritation to local products History of light-induced lesions such as urticaria, lupus erythematosus, light-induced rash, herpes simplex- Presence of active inflammatory dermatoses at the test site- Presence of neurological lesions at the test site- Active skin lesions・ History of sensitization or irritation to topical products ・ Frequent exposure to sun or tanning beds ・ Use of newly developed drugs within the last 6 months

Method 1. Operating procedure:
After the initial procedure, the minimum amount of erythema required to induce pigmentation in each volunteer was determined as described below.

a. Calculation of minimum erythema amount To evaluate the minimum erythema amount (MED), a preliminary test was performed on each volunteer. Six exposures were applied to each volunteer's unprotected skin, and each exposure was 12% higher than the previous exposure in a geometric progression. The median dose has already been determined by Fizpatrick Phototype and is shown in Table 1 below.

  After irradiation, the volunteer was withdrawn and instructed to return after 24 hours. Exposure data was recorded for each volunteer.

b. Read After irradiation, each volunteer is released and instructed to return within 24 hours, so that each volunteer's exposure site is kept constant for each volunteer from a predetermined distance in a vertical position. Read by illumination. The MED then decided for each candidate.

  Individual minimum erythema dose (iMED) was defined as the minimum ultraviolet (UV) irradiation necessary to produce a clearly defined contoured erythema at the exposed site and was used as a reference during the testing phase.

  Therefore, sub-sites that do not show erythema are a necessary criterion for test evaluation. If this does not occur, a new application must be performed to determine iMED.

c. Induction of pigmentation After iMD determination, each test site located next to the centerline of the back rib between the pelvis and shoulder ribs of the back was marked with a marker to the lying volunteers. The three ranges designated for application of the product were defined, that is, site B, site E, and site F. Each site was 35 cm ² (07 × 05 cm). Irradiation equivalent to 1.5 times the minimum erythema amount already calculated for each volunteer was applied to each of the defined areas. This application was repeated twice, so that each site was irradiated three times in total.

d. Application of product After irradiation, volunteers were withdrawn and instructed to return 72 hours later for photographic review and colorimetric evaluation. The subject was tested in triplicate for each of sites B, E, and F corresponding to three different irradiated regions to provide a total of three test sites and nine pointing regions per subject. After the evaluation, according to the following sequence, 2 mg of each test substance was applied once a day to the irradiation region indicated by the test site of each subject.
Site B: Hydroquinone 2%
Site E: topical cosmetic composition of the present invention Site F: negative control: site where product is not applied

  In order to optimize product penetration and avoid product movement, hand contact or UV exposure, the product application site was shielded with filter paper and held with translucent adhesive tape. Volunteers returned to the clinic for application, reading and evaluation according to Table II below.

e. Colorimetric evaluation Colorimetric evaluation was performed using a color difference meter. All measurements were performed in triplicate and the L ^* a ^* b ^* parameter average for each volunteer was recorded. The L ^* parameter was separately statistically analyzed as its value decreased.

f. Statistics The parameter L ^* was compared to see if there was a statistically significant difference between the treatment and control sites and between experimental points. This comparison was performed by Student's t test on the paired data.

Results Treatment was evaluated clinically and colorimetrically on the days of T7, T14 and T21. Site B containing a positive control (hydroquinone 2%) showed a colorimetric average for each experimental time as shown in FIG. FIG. 1 illustrates the progressive whitening over time that became statistically significant after 21 days. Table III below shows the results of a L ^* comparative test between the T0 average of region 1 (site B) and other experimental times. Table IV shows raw data of individual results for each volunteer's region 1 (site B) by L ^* , a ^* and b ^* for T0, T07, T14 and T21, respectively.

FIG. 2 illustrates the results obtained at site E, i.e., the application position of the evaluated topical cosmetic composition of the present invention. FIG. 2 is a diagram illustrating progressive whitening over time that becomes statistically significant after 14 days. Table V below illustrates the results of a L ^* comparative test between the T0 average of region 2 (site E) and other experimental times. Table VI shows raw data of individual results for each volunteer's region 2 (site E) by L ^* , a ^* and b ^* for each of T0, T07, T14 and T21.

FIG. 3 exemplifies progressive whitening (natural degradation of synthesized melanin) without any significant difference during the experimental time for control position site F, ie where nothing has been treated for irradiation. Yes. Table VII below shows the results of a comparative test of L ^* between the T0 mean of the control area (site F) and other experimental times. Table VIII shows the raw data of individual results for each volunteer's control area (site F) by L ^* , a ^* and b ^* for each of T0, T07, T14 and T21.

  FIG. 4 illustrates a comparison between the mean of the colorimetric values in treatments 1 and 2 and the control during the evaluation time. Table IX illustrates that only the topical cosmetic compositions of the present invention show a statistical reduction in pigmentation compared to the temporary reduction in pigmentation observed in the control group.

Discussion In experimental models where there is UV-induced pigmentation (melanogenesis) but pre-existing pigmentary dysfunction, clinical pigmentation in the treatment area will gradually decrease over time. All sites including untreated controls were evaluated using a colorimeter and showed a significant reduction in pigmentation by T21.

  This experiment was therefore conducted to relatively evaluate that the treatment was the quickest and caused the most significant depigmentation. Since all treatments were applied to each volunteer at the same time, the variation in melanogenesis ability was considerably reduced. Thus, depigmentation would have occurred at the same rate in all of each volunteer's test sites.

  From this premise, the whitening effect was clinically observed over time for each site, which already considered visual evaluation and comparative analysis.

  In order to increase the accuracy of these observations and enable objective, consistent and reproducible evaluations, colorimeters can be used as auxiliary instrument evaluations to detect differences that cannot be detected by the human eye did.

In a colorimeter, the L ^* parameter produced by the colorimetric measurement is an index directly related to skin lightness. The higher the value of L ^*, the brighter the evaluated area.

Since it deals with experimental melanogenesis, progression of depigmentation was predicted when treatment was assessed clinically and by a colorimeter. In control sites that were irradiated but not treated, hydroquinone showed a significant colorimetric improvement from T21 to L ^* , nevertheless, the whitening level was statistical when compared to hydroquinone T07 and T14. Scientifically low.

  Further examination of the data over time gave different results as follows. Hydroquinone: significantly improved from T21. The topical cosmetic composition of the present invention: significantly improved from T14, showing a statistically significantly higher whitening level when compared to the control. Thus, the topical cosmetic composition of the present invention provided a quicker and more significant whitening effect (higher whitening index) compared to hydroquinone.

Example 2
The following examples illustrate the preparation of a cream according to the invention as described herein.

  The composition is prepared as in Example 1. More specifically, after Premix E is added to the emulsion, Neolone PE (phenoxyethanol and methylisothiazolinone) and cyclomethicone are added under high shear homogenization and mixed for about 15 minutes. A thickener containing xanthan gum is added to the oil phase.

Example 3
The following examples illustrate the preparation of a cream according to the invention as described herein.

  This composition was prepared as in Example 1.

Example 4
The following examples illustrate generally applyable methods for administering the compositions according to the invention described herein.

  The topical cosmetic composition is administered topically to the skin of the subject treated by conventional means. This is preferably done by use of a serum or cream gel formulation. Thus, the topical formulation can be applied to the desired skin surface area using, for example, a fingertip.

  For topical administration of the cosmetic composition, subjects should first be instructed to gently clean the affected area and tap to dry. The topical cosmetic composition may then be applied directly to the affected area, or dispensed into the palm or appropriate container and the substance removed therefrom and applied to the skin area to be manually treated.

Example 5
The subject has undesirable skin pigmentation. The topical cosmetic compositions described herein are administered topically to undesirable pigmented areas of the subject's skin. It is expected that undesired pigmented areas of the subject's skin will be whitened.

Example 6
The subject has vitiligo. The topical cosmetic compositions described herein are administered topically to the remaining area of the subject's normal skin. It is expected that the remaining area of the subject's normal skin will be whitened to make the entire skin uniform.

Example 7
The subject has a stain due to age. The topical cosmetic compositions described herein are administered topically to the affected skin area of a subject. It is predicted that the spots due to age will be whitened.

  All publications cited herein are indicative of the level of skill of those skilled in the art to which the invention described herein pertains. All of these publications are incorporated herein by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

  Thus, while the invention has been described, it will be apparent that it can be altered or varied in many ways. Such changes and modifications are not to be regarded as a departure from the spirit and scope of the invention, and all such changes and modifications are intended to be included within the scope of the following claims.

Claims (30)

Philanthus extract,
A topical cosmetic composition comprising Belis extract and licorice extract. Philanthus Emblica extract,
A topical cosmetic composition comprising Belis Perennis extract and licorice extract.   The topical cosmetic according to claim 2, wherein the extract of Philanthus embrica comprises a fruit extract of Philanthus embrica, the extract of belith perennis comprises a flower extract of belith perennis, and the licorice extract comprises a root extract of licorice. Composition.   Based on the total weight of the composition, the philanthus embrica extract is present in an amount of about 0.5 wt% to about 2 wt%, the belith perennis extract is present in an amount of about 1 wt% to about 20 wt%, and the licorice extract The topical cosmetic composition of claim 2, wherein the product is present in an amount of about 0.01 wt% to about 1 wt%.   The topical cosmetic composition of claim 2, further comprising at least one sunscreen.   The topical cosmetic composition of claim 5, wherein the at least one sunscreen is present in an amount of about 0.5 wt% to 30 wt%, based on the total weight of the topical cosmetic composition. At least one sunscreen
A first sunscreen selected from the group consisting of methylenebisbenzotriazolyltetramethylphenol, diethylaminohydroxybenzoylhexylbenzoate, coated zinc oxide and combinations thereof; and ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, homo 6. The topical of claim 5, comprising a second sunscreen selected from the group consisting of ethylhexyl salate salicylate, octocrylene, polysilicone-15, butylmethoxydibenzoylmethane, menthyl anthranilate, ethylhexyldimethyl PABA, and combinations thereof. Cosmetic composition.   8. The first sunscreen is present in an amount from about 1 wt% to 20 wt% and the second sunscreen is present in an amount from about 1 wt% to about 10 wt%, based on the total weight of the topical cosmetic composition. The topical cosmetic composition described.   The topical cosmetic composition of claim 7, wherein the first sunscreen is methylene bis-benzotriazolyl tetramethylphenol and the second sunscreen is ethylhexyl methoxycinnamate.   The topical cosmetic composition of claim 2, further comprising water and at least one cosmetically acceptable excipient.   The topical cosmetic composition of claim 10, wherein water is present in an amount of about 3 wt% to about 95 wt%, based on the total weight of the composition.   At least one cosmetically acceptable excipient is an antioxidant, chelating agent, pH adjuster, emollient, thickener, preservative, emulsifier, wetting agent, humectant, suspending agent, fluorescent The topical cosmetic composition of claim 10, comprising one or more components selected from the group consisting of whitening agents, stabilizers, penetration enhancers, fragrances, colorants and combinations thereof. At least one cosmetically acceptable excipient,
An antibacterial agent comprising one or more components selected from the group consisting of butylated hydroxytoluene, sodium metabisulfite, butylated hydroxyanisole, ascorbic acid and their derivatives, sulfites, esters, tocopheryl acetate and combinations thereof Oxidant,
A chelating agent comprising one or more components selected from the group consisting of disodium edetate, EDTA, disodium EDTA, trisodium EDTA, tetrasodium EDTA and combinations thereof;
An emollient comprising one or more components selected from the group consisting of glycols, silicon-containing emollients and combinations thereof,
A thickener comprising one or more components selected from the group consisting of acrylic acid copolymer, acrylic acid, acrylamide, polysorbate, fatty alcohol, gum, silicon, carbomer derivative, cellulose derivative, and combinations thereof;
A preservative comprising one or more components selected from the group consisting of phenoxyethanol, methylisothiazolinone, paraben, imidazolylnidylurea and combinations thereof;
PH adjuster comprising one or more components selected from the group consisting of triethanolamine, aminomethylpropanol, sodium hydroxide and combinations thereof, and _C14-22 alcohol, _C12-20 alkyl glucoside and the like The topical cosmetic composition according to claim 10, comprising at least one component selected from the group consisting of emulsifiers comprising one or more components selected from the group consisting of:   The topical cosmetic composition of claim 2, further comprising a vitamin.   Formulation selected from the group consisting of serum, gel cream, cream, gel, lotion, foam, ointment, suspension, emulsion, effervescent liquid, dispersion, solution, bar, solid bar, paste, mask, milk and aerosol A topical cosmetic composition according to claim 2 comprising: Philanthus Emblica extract,
Skin whitening active ingredients, including Belis Perennis extract and licorice extract,
A topical cosmetic composition comprising at least one sunscreen and a cosmetically acceptable carrier.   17. The topical cosmetic composition of claim 16, wherein the skin lightening active ingredient is present in an amount of about 0.5 wt% to about 15 wt%, based on the total weight of the composition.   Based on the total weight of the composition, the philanthus embrica extract is present in an amount of about 0.5 wt% to about 2 wt%, the belith perennis extract is present in an amount of about 1 wt% to about 20 wt%, and the licorice extract The topical cosmetic composition of claim 16, wherein the product is present in an amount of about 0.01 wt% to about 1 wt%.   17. A topical cosmetic composition according to claim 16, wherein the cosmetically acceptable carrier comprises water and at least one cosmetically acceptable excipient. At least one sunscreen
A first sunscreen selected from the group consisting of methylenebisbenzotriazolyltetramethylphenol, diethylaminohydroxybenzoylhexylbenzoate, coated zinc oxide and combinations thereof; and ethylhexyl methoxycinnamate, isoamyl methoxycinnamate, homo 17. The topical of claim 16, comprising a second sunscreen selected from the group consisting of ethylhexyl salate salicylate, octocrylene, polysilicone-15, butylmethoxydibenzoylmethane, menthyl anthranilate, ethylhexyldimethyl PABA, and combinations thereof. Cosmetic composition. Philanthus Emblica extract,
A topical cosmetic composition comprising a skin whitening active ingredient comprising a Belis Perennis extract and a licorice extract, and a non-skin whitening ingredient comprising at least one sunscreen.   A method of whitening skin pigmentation in a subject comprising topically administering a therapeutically effective amount of the topical cosmetic composition of claim 1 to the skin of the subject in need thereof.   23. The method of claim 22, wherein the topical administration comprises administering at least once per day for at least 2 weeks, and the skin pigmentation is whitened.   23. The method of claim 22, wherein the topical administration comprises administering at least twice per day for at least 2 weeks, and the skin pigmentation is whitened.   24. The method of claim 23, wherein administering at least once per day comprises administering once in the morning or night.   25. The method of claim 24, wherein administering at least twice per day comprises administering once in the morning and once in the night.   17. A method of whitening skin pigmentation in a subject comprising topically administering a therapeutically effective amount of the topical cosmetic composition of claim 16 to the skin of the subject in need thereof.   A method of treating a skin disorder or condition in a subject comprising topically administering to the skin of a subject in need thereof a therapeutically effective amount of the topical cosmetic composition of claim 2.   29. The skin disorder or condition is selected from the group consisting of hyperpigmentation, hyperpigmentation, freckles, moles, age spots, idiopathic melasma, photosensitization and scarring after injury, and vitiligo. the method of.   17. A method for treating a skin disorder or condition in a subject comprising topically administering a therapeutically effective amount of the topical cosmetic composition of claim 16 to the skin of the subject in need thereof.

Images